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Abstract 
 
The cancer stem cell (CSC) hypothesis provides a hierarchical model which explains the 
observed heterogeneity of cancers cells within a tumor.  CSCs sit at the apex of the tumor 
hierarchy and are uniquely capable of initiating tumor formation.  These cells retain two 
key properties: self-renewal, which allows for long term proliferation potential and the 
capability to differentiate into the heterogeneous cell lineages found within a tumor.  In 
order to truly cure patients it is necessary to not only reduce tumor volume but eliminate 
all cell populations within the cancer. Accumulating evidence suggests that breast cancers 
are driven by CSCs and that this model can address two critical needs associated with 
drug resistance in patients to improve overall survival.  In this report we demonstrate that 
in triple negative breast cancers (TNBCs) current chemotherapy fails to eliminate, and 
may even expand, breast CSCs through activation of the NF-kB signaling node.  
Similarly, we demonstrate in HER2+ breast cancers with PTEN inactivation that the 
generation of trastuzumab resistance results in the dependence on an IL6/STAT3/NF-kB 
positive feedback loop.  Activation of this signaling loop induced the epithelial to 
mesenchymal transition, expanded BCSCs, and results in a subtype conversion from 
HER2+ to TNBC.  In these contexts, current treatment strategies are simply delaying 
disease progression rather than attacking the roots of breast cancer.  Using the natural 
product sulforaphane (SF) which has been demonstrated to inhibit NF-kB signal 
transduction, we demonstrate that this compound can be used to address these issues.  In 
 xi 
 
this report SF preferentially inhibited TNBC cell lines and CSCs. Due to its inhibition of 
NF-kB, SF reduced IL6-mediated BCSC expansion induced by docetaxel treatment.  
Consequently, combination of the two therapies dramatically reduced both tumor volume 
and CSCs.  In trastuzumab resistant, PTEN deficient, breast cancers NF-kB inhibition by 
SF was sufficient to eliminate both of these populations.  By analyzing the transcriptional 
landscape of trastuzumab sensitive and resistant cell lines in the presence of SF with 
RNA sequencing, MEOX1 was identified as a novel drug target capable of regulating 
bulk cell line proliferation and breast CSC self-renewal in trastuzumab resistant breast 
cancer and a subset of TNBCs. 
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Chapter 1 
Background  
Abstract 
The cancer stem cell (CSC) hypothesis presents a fundamentally different paradigm for 
cancer treatment. CSCs reflect a small fraction of tumor initiating cells capable of 
sustained self-renewal and differentiation to form the heterogeneous tumor bulk. In order 
to cure cancer, it is necessary to eliminate CSCs in addition to differentiated cancer cells 
to decrease metastasis, reduce recurrence, and improve patient survival. In this chapter, 
we review signaling pathways which regulate CSCs, including Wnt, Hedgehog, and 
Notch, as well as interactions of CSCs with the tumor microenvironment. Further, we 
discuss methods to isolate CSCs and demonstrate ways to identify therapeutic efficacy 
toward eliminating these cells. Natural products which regulate key signaling pathways 
with CSCs are also highlighted. Applying the CSC model to breast cancers we identify 
specific clinical issues which can be addressed by inhibition of these cells.  Finally, using 
the natural product sulforaphane we propose three specific aims which can be used to 
overcome such issues.     
Introduction 
Currently, cancer is the second leading cause of death in the United States and is 
estimated to be the leading cause of death worldwide by the World Health Organization. 
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Tumorigenesis occurs when normal cells accumulate sufficient mutations to allow for 
sustained proliferation, evasion of apoptosis, and ultimately tissue invasion and 
metastasis (1). Substantial progress has been made with respect to the treatment of 
primary tumors using surgery, chemotherapy, radiation therapy, and radiofrequency 
ablation. However, the advancement of cancer to an invasive or metastatic stage is 
frequently associated with a poor patient prognosis and remains a critical hurdle in the 
treatment of the disease (2). The heterogeneity of the cancer cells pose great challenges 
for effective treatment using conventional therapy as all cancer cells do not respond to 
therapy homogeneously, leaving the potential for recurrence (3).  
A mechanistic understanding of the observed heterogeneity in tumors has yet to be fully 
elucidated, and has historically been a subject of controversy within the cancer research 
field (4). Since the observation that a single murine leukemia cell was capable of 
generating a tumor graft, there have been numerous reports illustrating that the capacity 
for tumor initiation is heterogeneous within subpopulations of cancer cell lines and 
primary tumors.  Strikingly, in a human autotransplantation study by Southam and 
Brunschwig, it was demonstrated that a minimum of one million unsorted cells from 
primary tumors were required to form secondary engraftments and that the frequency of 
initiation varied by the form of carcinoma (5). The stochastic model predicts that 
phenotypic differences among tumor cells are influenced by random intrinsic and 
extrinsic factors and that every cell has an equal likelihood of tumorigenic 
transformation(6).  Interestingly, a recent breast cancer study argues that this model may 
still have some relevance today (7).  However, over the past 50 years, mounting evidence 
in leukemias as well as several solid cancers including brain, breast, colon, head/neck, 
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liver, pancreas, prostate, and ovarian indicate that tumors are organized in a hierarchical 
manner somewhat paralleling their organ of origin (8-11).    
Advances in hematopoietic stem cell (HSC) research established that HSCs are capable 
of sustained self-renewal, proliferation, and differentiation (6).  These results were later 
confirmed after the isolation of mouse hematopoietic stem cells based on a variety of 
phenotypic markers (12). Analogous studies in Acute Myeloid Leukemia (AML) (13, 14) 
ultimately led to the discovery of AML cancer stem cells (CSCs) in 1994 by John Dick’s 
group (15).  The hierarchical CSC model proposes only a small fraction (typically <10%) 
of cells within the cancer, known as CSCs, are capable of tumor initiation and unlimited 
self-renewal through asymmetric division(4). Furthermore, these populations are 
responsible for differentiation into the other heterogeneous lineages found within a 
tumor. Current studies have shown, using this functional definition, that CSCs are 
resistant to conventional cancer treatments such as radiotherapy and chemotherapy (16). 
This model then requires a paradigm shift in the way in which cancer is treated. In order 
to effectively eliminate the roots of cancer, CSC specific inhibitors must be developed.  
Epidemiological studies have shown strong correlations between consumption of certain 
dietary products and herbal remedies with reduced risk of developing a host of cancers 
(17-19). As a result natural produces with known mechanisms of action and, those 
recently discovered to be biologically active, have gained considerable attention as agents 
capable of modulating CSCs (20). Here we briefly review CSC biology and the 
mechanisms by which natural products modulate essential CSC pathways.  The potential 
of combining these CSC targeting natural products with conventional chemotherapy 
agents known to eradicate more differentiated cancer cells will also be discussed. 
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Therapeutic Implications of the CSC Model 
While many advances have been made in terms of surgical treatment and diagnosis, 
recurrence and metastasis still remain as major obstacles to overcome (21, 22).  Applying 
the CSC model not only provides significant insight into why conventional therapy fails, 
but also provides druggable targets which may unlock the key to curing this debilitating 
disease (23).  Clinical trial endpoints for the approval of chemotherapy drugs have 
historically been based on improvements in overall survival or more commonly by direct 
tumor assessments (24).  With respect to direct tumor assessments, three common 
methods exist for quantifying results: objective response rate (ORR), time to progression 
(TTP), and progression-free survival (PFS) (25).  The RECIST criteria can be used to 
measure therapeutic response, although together, all of these results are predominantly 
based on tumor size (26).  Using these statistics as endpoints of clinical trials has resulted 
in identification of compounds which can reduce the size of primary tumors, but may 
have little to no effect on CSCs.  
The CSC model predicts that the bulk of a tumor is made up of differentiated tumor cells 
while only a small fraction are CSC (27, 28) responsible for metastasis, recurrence, and 
drug resistance (29, 30).  However, because of the inherent differences in drug response 
between these two populations, it is possible that currently approved chemotherapeutics 
are only effective against the more differentiated tumor cells representing the bulk of the 
tumor (Fig. 1.1).  Indeed, recent literature suggests that most current chemotherapeutics 
(such as cisplatin, doxorubicin, and docetaxel) and radiation therapy lack the ability to 
kill CSCs (31-33).  Alarmingly, these conventional therapies have been demonstrated to 
even expand the population of CSCs (34, 35).   Consequently, tumor regression may be 
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an inadequate endpoint for clinical trials because the remaining CSCs, either from the 
primary tumor or at sites of micrometastases can simply initiate new tumors, and 
potentially pass on a drug resistant phenotype (16).   Therefore, strategies which inhibit 
CSCs by targeting critical CSCs signaling pathways (36-38) are essential to treatment.   
While the CSC model predicts that elimination of CSCs will prevent recurrence and 
metastasis, the removal of the bulk tumor mass is also beneficial.  Cancer cells that are 
more differentiated than CSCs may retain limited proliferation potential, indicating that 
tumor growth may still occur.  It is also plausible that these genetically unstable tumor 
cells could obtain additional mutations, or stochastic influence (7), sufficient to regain 
self-renewal capacity, consequently little would be done to cure the cancer. Bulk tumor 
volume is also responsible for unwanted symptoms in patients. For instance, solid 
neoplasms of the brain lead to increased intracranial pressure while tumor size in patients 
diagnosed with renal angiomyolipoma is correlated with aneurysm formation (39).  Thus, 
to improve the overall quality of life and reduce future risk elimination of both CSCs as 
well as the more differentiated cancer cells within a tumor is required.   
Identifying CSCs and Evaluating Therapeutic Efficacy  
With the successful demonstration that AML stem cells could be identified using 
monoclonal antibodies targeted to the cell surface markers (CD34+/CD38-) (12) and 
isolated using fluorescent activated cell sorting (40), the CSC model was rapidly applied 
to solid tumors. While a complete review of all CSC markers is beyond the scope of this 
review, table 1 summarizes markers used to identify CSCs in a variety of solid tumors as 
well as the number of cells needed for engraftment in immunocompromised mice.  It is 
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important to note that these cell surface markers vary based on the origin of tumor as well 
as the molecular subtype of the cancer.  For instance, CD44+/CD24-/lin- cells isolated 
from primary breast cancer patients preferentially initiate tumors in NOD/SCID mice 
with as few as 100 cells (11).  When comparing the expression of these markers in basal 
and luminal type breast cancer cell lines Fillmore and Kuperwasser maintain that this 
population more accurately describes a basal cellular phenotype (41).  It was further 
shown that the CD44+/CD24-/ESA+ fraction better reflect the CSC properties of tumor 
initiation, quiescence, tumorsphere formation, and chemo-resistance in basal type cell 
lines.  These results demonstrate a need for general molecular markers of CSCs.   
Aldehyde dehydrogenase (ALDH) has gained considerable attention and has 
demonstrated utility in identifying stem and progenitor cells in both normal and 
malignant tissue, as well as across species.  The activity of this enzyme is responsible for 
intracellular detoxification of aliphatic and aromatic aldehydes via the oxidation to 
carboxylic acids (42).  One such substrate, retinaldehyde is a critical precursor to retinoic 
acid, which can further direct differentiation of stem cells via GSK3-β signaling (43).  
ALDH positive cells contain normal murine and human hematopoietic (44, 45), neural 
(46), and mammary stem cells (28).  Furthermore, in primary tumors as well as cell lines, 
ALDH+ sorting, alone or in conjunction with cell surface markers can be used to isolate 
CSCs for head and neck (47), mammary (28), pancreatic (48), and ovarian cancers (49).    
At the root of defining these populations as CSCs is the observation that in all cases, the 
ALDH+ cells preferentially initiate tumor formation in vivo (using serial dilution analysis 
in a murine xenograft model), are capable of sustained self-renewal (demonstrated by 
serial passages in immunocompromised mice), and differentiation to form the bulk of 
 7 
 
tumor mass (ALDH+ cells regenerate heterogeneity of primary tumor as opposed to 
ALDH- cells) (28, 50).  In breast cancer cell lines, Charafe-Jauffret et al. utilized 
Affymetrix microarrays to illustrate that ALDH+ cells overexpress known stem cell self-
renewal genes such as NOTCH2 and NFYA (51).  Conversely, ALDH- populations 
exhibited higher levels of genes responsible for apoptosis and differentiation.   
 
While the search for a universal CSC marker is appealing, it is essential to note that the 
term CSC is a functional definition, as these cells may arise from any number of 
mutagenic transformations.  Consequently, monitoring the efficacy of CSC-targeted 
drugs may not be possible with the use of surface markers or enzymatic activity alone. 
Neuronal stem cell studies demonstrated that primitive neuronal cells are anchorage 
Table 1. Prospective Identification of CSC markers in solid tumors. 
Origin of tumor CSC Marker 
CSCs required for 
initiation Reference 
Brain CD 133+ 100 (57, 58) 
Breast CD44+CD24-(EpCAM+) 
ALDH+ 
CD44+CD24-ALDH+ 
100 
500 
20 
(11, 28, 41) 
Colon EpCAM+CD44+ 200 (59) 
Head and Neck CD44+ 
ALDH+ 
5000 
500 
(9, 60, 61) 
Pancreas CD44+CD24+ESA+ 
ALDH+ 
100 
100 
(48, 50) 
Prostate CD44+ 100-1000 (62) 
Ovaries CD133+(ALDH+) 2000 (63) 
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independent and produce floating colonies called neurospheres when grown in non-
adherent conditions (52).  Similarly, the self-renewal capacity of CSCs can be 
demonstrated in vitro through tumor sphere formation (53). Primary tumors or cell lines 
are dissociated into single cell suspensions and placed in serum free media containing 
bFGF and VEGF.  In these nonadherent culture conditions differentiated cells will 
undergo anoikis, while CSCs survive, self-renew, and differentiate to produce a spherical 
cluster enriched in stem and progenitor cells (54). Under no external stress, tumorspheres 
can be dissociated and passaged to further generations.  In the presence of therapeutics 
that inhibit CSCs, sphere size and formation frequency will be reduced (55).  Treated 
spheres are then dissociated and passaged for a second generation in the absence of 
therapeutic; alterations in sphere formation then reflect the self-renewal capacity changes 
in the CSCs.   
The “gold standard” for assessing CSC inhibition is demonstrating a reduction in 
xenograft take when tumors cells are implanted in NOD/SCID mice (56).  In contrast, 
reduction in tumor growth in vivo is not an appropriate measurement to quantify CSC 
reduction by therapeutics.  In a model of advanced carcinogenesis, where tumors are 
already fully established, the CSC population represents typically less than 10% of tumor 
bulk.  Thus, even complete abolition of CSCs may not result in reduced tumor volume.  
In order to evaluate a therapeutics effect on CSCs, it is necessary to dissociate the 
primary tumor and engraft the serially diluted cells in secondary animals.  Therapeutic 
response of the CSCs can then be seen through reduction in tumor initiation and growth.   
Targeting CSC signal transduction 
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Developmental biology studies have revealed three major signaling pathways, Wnt, 
hedgehog (Hh), and Notch, are essential for the self-renewal and differentiation 
properties of stem cells.   Due to the phenotypic similarities of CSCs to their normal stem 
cell counterparts, it is no surprise that these pathways also regulate CSCs and targeting 
each one has demonstrated efficacy toward eliminating cancers.  Several key signaling 
nodes also act as points of cross talk between these pathways and are known to be 
regulated by natural products. Furthermore, dynamic interactions of CSCs with the tumor 
microenvironment reveal a niche which can be exploited for drug discovery.  Figure 1.2 
summarizes the critical components of each pathway and demonstrates the interconnected 
nature of signaling in CSCs.  Figure 1.3 highlights natural produces capable of inhibiting 
these pathways. 
The WNT signaling pathway 
Purified Wnt3A from mouse L cells, as well as up regulation of downstream transcription 
factor β-catenin, has shown an increase in HSC proliferation and reduced differentiation 
in vitro (64, 65).  In the intestinal epithelium, Wnt target gene Lgr5 is exclusively 
expressed by stem cells in the crypt base capable of generating all epithelial lineages, 
additionally similar results were found in the colon and pyloric glands (66, 67).  
Prolonged culture of mammary SC enriched populations, in the presence of Wnt3A, were 
capable of regenerating the cleared fat pads of recipient mice whereas those without Wnt 
proteins were not (68).  Additionally, a cell-surface glycoprotein known as CD44 
implicated in hematopoiesis (69) and tumor progression is modulated by Wnt signaling 
components APC and Tcf4 (70, 71).   
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Enhanced activation of Wnt signaling has also been observed in a host of cancers 
including both acute myeloid and chronic lymphoid leukemias (72, 73).  One of the most 
well studied changes in Wnt signaling is the loss of function of the APC gene leading to 
Familial Adenomatous Polyposis (74).  Furthermore, one of the most common 
genetically engineered mouse models for breast cancer study (MMTV-Wnt-1) develops 
mammary tumors via deregulation of Wnt signaling leading to aberrant β-catenin 
activation.  Consistent with reports of human breast cancer, these mice contain a 
subpopulation of highly tumorigenic CSCs (75).  To assess targets within the Wnt 
pathway it is essential to know the mechanism by which signal transduction occurs (76-
78).   
The conical Wnt signaling pathways contains two receptors, the seven transmembrane 
domain Wnt binding protein Frizzled (Fz) and its co-receptor low density lipoprotein 
receptor-related protein (LRP).  Associated with the intracellular domain of Fz is the 
scaffold protein Dishevelled (Dvl), which serves as a platform for assembly of signal 
transduction proteins (79).  In the absence of Wnt stimulation a cytoplasmic protein 
complex exists in which transcriptional activator and cytoskeletal linker β-catenin is 
phosphorylated and subsequently eliminated by ubiquitination and proteasomal 
degradation.  Within this complex are the scaffold protein Axin, the human tumor 
suppressor adenomatosis polyposis coli (APC) protein, and the kinase regulating β-
catenin degradation GSK-3β.  In the event of Wnt protein binding to Fz, LRP and Dvl 
become phosphorylated by GSK-3β and casein kinase (CK) proteins (80).  Axin also 
associates with LRP at the cell surface and consequently β-catenin is no longer degraded.  
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Translocation of β-catenin to the nuclease occurs, where it acts with LEF/Tcf 
transcription factors to regulate Wnt target gene expression.   
Natural products that modulate Wnt signaling have proven to be effective at targeting 
CSCs.  Piperine, an alkaloid derived from black and long peppers, has been shown to 
reduce lung metastasis in a melanoma mouse model (81) as well as prevent chemically 
induced lung carcinogenesis (82).  Prevention of metastasis and tumor initiation by this 
compound indicates an effect on CSCs.  These results were confirmed in both primary 
breast tissue and breast cancer cell lines by Kakarala et al. using mammospheres 
formation and the BCSC marker ALDH1 (83).  In this study, the observation that little 
response was shown in differentiated cells indicates a mechanism of action primarily 
important in SCs.  A LEF/Tcf green fluorescence protein reporter was used in the luminal 
cell line MCF7 to indicate that inhibition of Wnt signaling was mediating piperine’s 
effect.  
High-throughput screening (HTS) has also been used to identify natural products that 
block Wnt signaling.  Lepourcelet et.al. demonstrate that high-throughput ELIZA can be 
utilized to determine the binding of β-catenin to Tcf4 (84).  After screening 
approximately 7,000 natural products and 45,000 synthetic compounds, Eight natural 
products were capable of obtaining IC50 values less than 10 μM whereas no synthetic 
compounds produced the same results.  Selective inhibitors of BCSCs have also been 
identified by HTS.  Immortalized human mammary epithelial cells undergoing an 
epithelial to mesenchymal transition (EMT) adopt SC-like properties and markers (85).  
By inducing this phenomenon Gupta et al. identified four compounds with consistent 
selectivity toward the EMT-induced cells and one compound salinomycin was confirmed 
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to eradicate BCSCs (35).  Recent studies in chronic lymphocytic leukemia demonstrate 
that this potassium ionophore downregulates LRP, preventing its activating 
phosphorylation as well as reducing Wnt target gene expression with nanomolar efficacy.   
The Hedgehog signaling pathway 
The Hedgehog (Hh) signaling pathway has been known for some time to regulate tissue 
polarity, embryonic patterning, and organ development.  Experiments in the development 
of Drospohila demonstrated that cells in posterior limb compartments release Hg to 
mediate development in anterior compartments indirectly through Wnt signaling (86).  In 
mammals three secreted proteins known as Desert hedgehog (Dhh), Indian hedgehog 
(Ihh), and Sonic hedgehog (Shh) are endogenous activators of the Hh signaling cascade 
(87).     Of these, Shh facilitates differentiation in the mouse neural tube in a gradient 
fashion via production and secretion from the notochord and floor plate (87).  
Additionally, activation of the Gli2 transcription factor by Hh signaling in mammary 
stroma supports normal ductal formation (88).   
The influence of Hh on cell fate indicates that it is a key factor in differentiation and 
plays a role in SC and CSC biology.  Using primarily neurosphere culture and BrdU 
labeling to monitor quiescence, Palma and Altaba demonstrated embryonic and postnatal 
neocortical cells from mice contained stem cell like properties (89).  Furthermore, these 
cells were reliant upon Shh-Gli and EGF to maintain self-renewal.  In a companion study 
Palma et al. demonstrated that the Shh-Gli signaling is critical for the regulation of stem 
cells in the adult mouse subventricular zone (90).  The generation of Ihh
-/-
 embryonic 
mice also demonstrated a reduction in the size of intestinal microvilli, and was attributed 
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to lower proliferation rates in the stem cell compartment(91). With respect to BCSCs, 
primary human tumors produce higher mRNA levels of Hedgehog signaling receptors 
(PTCH/SMO) and transcription factors (GLI1/GLI2) (92).  Further, in glioma CSCs 
pharmacological inhibition of Hh-Gli signaling prevents self-renewal in vitro and tumor 
growth in xenograft models (53).   
The Hh signaling pathway exists typically “off state”, and like the Wnt pathway contains 
two receptors smoothened (SMO) and patched (PTCH).  In the absence of one of the 
three hedgehog ligands, PTCH binds and prevents association of SMO with the cell 
membrane.  The off state is also characterized by the sequestration of GLI transcription 
factors to microtubules by SuFu and Kif7.  This state allows for GLI phosphorylation by 
PKA, CK, and GSK-3β subsequently followed by degradation.  Binding of Hh ligands to 
PTCH relieves inhibition of SMO, allowing for translocation to the microtubule.  SMO 
then prevents the action of kinases on GLI, allowing it to translocate to the nucleus and 
activate transcription (93-95).    
The natural product cyclopamine (CYC), derived from Veratrum Californicum, has been 
showed to target the Hedgehog pathway and inhibit transcription.  Previous work has 
shown CYC acts as an antagonist to SMO by direct binding, altering the macromolecular 
conformation.  Inhibition of SMO with CYC locks the Hh pathway in the “off state” 
preventing transcription (96).  With glioblastoma cell lines CYC reduces neurosphere 
formation and prevents engraftment in mice (97).  In an advanced model of pancreatic 
cancer CYC alone was insufficient to deplete the CSC compartment.  However, when 
combined with conventional chemotherapy agent gemcitabine and mTOR inhibitor 
rapamycin the CSC levels were virtually undetectable both in vitro and in vivo (98). 
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The Notch signaling pathway 
Notch receptors are key cell coordination proteins that help create complex tissue 
organization and patterning.  In early developmental systems, Notch signaling drives cell 
fate determination between contacting cell dimers, in which both cells initially carry 
equal propensity for lineage specialization (99).  For example, during neurogenesis, 
contacting cells expressing both Notch receptors and ligands have equal pull towards a 
given differentiation pathway.  Local variations in expression will cause one cell to 
express higher levels of Notch ligands, thereby causing Notch mediated inhibition of 
neuronal development in the neighboring cell (100, 101). This “lateral inhibition” helps 
to drive local distinctions in cell specialization, creating tissue complexity that is seen in 
a variety of organ systems, such as the retina in flies and tip-cell formation during 
angiogenesis (102-104).  
The Notch protein is a transmembrane receptor heterodimer, with each monomer 
containing either the extracellular or intracellular domain. Comprised of four receptors 
(Notch1-4), the Notch family can interact with any of the five Notch transmembrane 
ligands: Jagged1 and 2, Delta-like 1, 3, and 4. The extracellular domain of these ligands, 
expressed on the signaling cell, interacts with the extracellular domain of the Notch 
receptors.  Binding of effector ligand induces a conformational change in the Notch 
protein allowing for cleavage by the membrane bound metalloprotease TACE/ADAM17.  
The Notch receptor is further processed by γ-secretase enzymes, which release the Notch 
Intracellular Domain (NICD) for translocation to the nucleus.  In the nucleus, the NICD 
facilitates conversion of the CSL repressor complex into active transcriptional complex 
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after recruitment of the MAML1 co-activator protein, leading to a wide assortment of 
downstream signaling (105-107).  
Aberrant regulation of Notch signaling can arise through different mechanisms.  
Overexpression of Notch ligands, such as Jagged1, have been linked to enhanced Notch 
activity and correlated with poorer prognosis in breast cancers (108-110).  Loss of the 
negative regulator of Notch signaling, Numb, has also been observed, correlating with a 
higher tumor grade (111).  Constitutive activation of Notch can also occur, although this 
is more common in hematological cancers where cell-cell interactions are less frequent 
(112-114). Increased Notch activity influences a number of tumorigenic processes, such 
as cell-cycle progression, inhibition of apoptosis, and enhanced drug resistance.  Notch 
activation has been shown to stimulate both Cyclin D1 and c-Myc, potent cell cycle 
regulators (115-117). Upregulation of Hes-1, a downstream Notch target gene, drives 
several changes to other regulatory pathways.  Hes-1 potentiates cell-cycle progression 
by repressing transcription of cell-cycle kinase inhibitors (118-120).  Hes-1 mediated 
repression of PTEN can lead to inhibition of apoptosis and enhanced survival signaling 
via PI3K/Akt in different cancer cells (121-123).   
Notch activity has been implicated in cell fate determination for both stem and cancer 
stem cells.  Normal mammary stem cells stimulated with a DSL peptide (a surrogate 
Notch ligand) had an increased capacity for generating mammospheres (124). Neuronal 
precursor cells were maintained in an undifferentiated state through interaction of Notch 
with HIF1a (125).  Both brain and breast CSCs were shown to require Notch activity for 
self-renewal, as treatment with gamma secretase inhibitors (GSI) reduced the ability of 
these CSCs to form spheroid colonies (126, 127).  Notch activity has also been observed 
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during EMT, a process believed to bestow stem-like qualities on differentiated cells.  The 
downstream Notch target gene SLUG was shown to induce EMT in breast cancer cells 
stimulated with Jagged1 (128).  
Disruption of Notch activity with natural products has been demonstrated in a variety of 
cancer cell types. Both curcumin, a polyphenol found in turmeric, and genistein, a soy 
isoflavone, were found to disrupt Notch1 mediated activation of NF-κB, leading to 
increased apoptosis in pancreatic cancer cells (129-131). Resveratrol, another well-
known polyphenol, induced apoptosis in MOLT4 acute lymphoblastic leukaemia cells by 
Notch1 inhibition and subsequent activation of p53 (132). Withaferin-A and Celastrol, 
triterpenes known for their anti-inflammatory properties, have also been reported to block 
Notch1 activity in cancer cells (133, 134).  Further, both are known to inhibit the function 
of BCSCs, albeit with varying reported mechanisms of action which may be a result of 
the importance of certain signaling nodes in multiple CSC signal transduction pathways 
(135, 136).  
Targeting signaling nodes involved in crosstalk between pathways 
Critical pathways within CSCs are interconnected and converge at several key regulatory 
nodes.  Mutations in the tumor suppressor phosphatase and tensin homolog (PTEN) gene 
are common in a host of human cancers.  Without the function of PTEN to turn off 
phosphoinositide-3 kinase (PI3K) signaling the kinase Akt can be constitutively 
activated, resulting in cellular changes in survival and metabolism (137).  Furthermore, 
Akt is capable of inactivating GSK-3β through phosphorylation(138) and as a 
consequence relieving inhibition of both Wnt and Notch signaling.  Korkaya et al. have 
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utilized this principle to demonstrate that inhibition of Akt with the alkylphospholipid 
perifosine prevents β-catenin activation and subsequently eliminates BCSCs in vivo 
(139).  Perifosine is currently in phase III clinical trials in combination with Capecitabine 
for the treatment of patients with refractory advanced colorectal cancer.  
Previous work in our laboratory has shown that the dietary isothiocyanate sulforaphane 
(SF) selectively eliminates BCSCs in vitro at concentrations as low as 1 μM (55).   
Further study into the regulation of CSCs with SF revealed a reduction in the level of 
Akt, phospho-GSK-3β, and β-catenin.  Introduction of a GFP β-catenin reporter into the 
luminal B cell line MCF7, cultured as mammospheres, was used to confirm the reduction 
in β-catenin mediated transcription.  In vivo, SF significantly reduced primary tumor 
growth and prevented tumor engraftment into secondary mice demonstrating that BCSCs 
were eliminated.   
The molecular chaperone heat shock protein 90 (Hsp90) has become a promising target 
for eliminating multiple forms of cancer.  Due to the role of assisting protein maturation 
and the staggering number its oncogenic clients, such as those in the PI3K/Akt pathway, 
inhibition of HSP90 may serve as one target that can disrupt multiple pathways.  The 
prototypical HSP90 inhibitor geldanamycin was isolated from Streptomyces 
hygroscopicus and demonstrated efficacy across many forms of cancer (140). However, 
in vivo toxicity limited its potential use and derivatives such as 17-AAG were created 
(141). This compound has been shown to preferentially inhibit glioma stem cell growth, 
indicating the potential use HSP90 inhibitors as CSC therapeutics (142). Recently, we 
have shown that SF synergistically block HSP90 function with 17-AAG through 
simultaneous disruption of the co-chaperone complex and antagonism of the N-terminal 
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ATP binding pocket respectively (143).  Consequently, client proteins Akt, mutant p53, 
Raf-1, and Cdk4 were all down regulated, suggesting another possible mechanism for SF 
function in pancreatic cancer. 
Preventing CSC-Microenvironment Interactions 
The transcription factor NF-κB, has been shown to be critical to the function of AML 
CSCs (144).  In addition to the conical tumor necrosis factor activation, NF-κB is a key 
signaling molecule in the pathways responsible for mediating interactions of CSCs with 
the tumor microenvironment.  In vivo, mesenchymal stem cells from bone marrow traffic 
to the site of tumor formation and regulate BCSC by releasing cytokines (145).  Two of 
these, IL-6 and IL-8, bind to their respective receptors IL-6R/gp-130 and CXCR1 on 
tumor cells producing a signaling cascade through NF-κB (146).  This in turn stimulates 
further cytokine production, generating a positive feedback loop that can then perpetuate 
CSC self-renewal (147). Inhibition of NF-κB has been accomplished using the 
sesquiterpene lactone parthenolide, which induces apoptosis in leukemia stem cells in 
vitro and inhibits tumor initiation in NOD/SCID mice with minimal damage to normal 
hematopoietic cells (148). These promising results have led to the exploration of orally 
active analogs of parthenolide.   
 Hypoxia-inducible factors (HIFs) regulate many cellular processes including cell 
metabolism and stem cell differentiation in hypoxic environments.  With respect to CSCs, 
Keith and Simon proposed that HIFs may play a critical role by enhancing expression or 
activity of critical signaling pathways such Notch (149).  In a recent study it was 
demonstrated that in human AML samples HIF-1α is selectively activated in the CSC 
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compartment (150).   Confirming the hypothesis of Keith and Simon, pharmacological 
inhibition of HIF activity reduced Notch mediated production of Hes1.  This was 
accomplished in part through the use of echinomycin, a cyclic peptide isolated from 
Streptomyces echinatus. Echinomycin, originally discovered by high-throughput 
screening, prevents HIF-1 binding to DNA preventing hypoxia induced gene expression 
(151).  Treatment of primary AML from human with echinomycin in xenograft mice 
remarkably eliminates virtually all CSCs, preventing serial transplantation (150).  These 
results were obtained at doses 50 times lower than those tolerable in human phase II 
clinical trials and prompt further investigation into the use of echinomycin as a CSC 
targeting therapeutic (152).    
Addressing Critical Needs for Breast Cancer Therapy with Sulforaphane and the 
Cancer Stem Cell Model 
Breast cancer remains the second leading cause of cancer related deaths among women in 
the United States with 232,670 new cases diagnosed each year and 40,000 annual deaths 
(153).  This disease progresses through a multistage process characterized by the 
development of a hyperplasia which progresses to an in situ carcinoma that ultimately 
invades surrounding tissue and spreads throughout the body causing distant metastasis 
(154).  Advances in surgical techniques, radiation therapy, and novel therapeutics have 
led to an increase of overall survival rates (155).  Unfortunately metastatic breast cancer 
remains largely an incurable disease with on average a 25% five-year survival rate.  Like 
most cancers this disease is highly variable from patient to patients but can be classified 
into four major subtypes based on the expression of the estrogen (ER), progesterone 
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(PR), and HER2 receptor expression within a given malignancy, which can guide the use 
of small molecule or biologic intervention(156).   
The most commonly diagnosed breast cancer (42-59% of patients) is referred to as 
Luminal A, which expresses ER and/or PR with low expression of the proliferation 
marker Ki-67(157).  Luminal A breast cancers are tend to have the best prognosis for 
patients and are susceptible to targeted endocrine therapies.  Like Luminal A breast 
cancers, Luminal B breast cancers express ER and/or PR but are characterized by higher 
proliferation as evident by Ki-67 and are less prevalent (6-19%).  While these diseases 
tend to have an overall worse prognosis still several targeted treatment options are 
available to patients. Diseases exhibiting the worst prognosis are the HER2+ and triple 
negative breast cancer (TNBC) subtypes.  HER2+ breast cancers account for 7-12% of 
patients and is diagnosed by either high HER2 staining by immunohistochemistry (3+, 
IHC), or boarder line IHC staining (2+) with a demonstrated HER2 gene amplification 
identified by fluorescence in situ hybridization. Patients with this disease will most 
commonly be treated with a combination of HER2 targeted therapy with conventional 
cytotoxic chemotherapy(158).  Finally, TNBC is characterized by the lack of ER, PR, and 
HER2 and predominantly expresses basal/myoepithelial cytokeratins.  Due to the lack of 
expression of receptors that can be targeted by therapy these breast cancers are limited to 
treatment with some combination of cytotoxic chemotherapy.  Further, by definition the 
term TNBCs is exclusionary in nature, meaning that any form of breast cancer which 
does not express ER, PR, or HER2 is combined into this one subtype.  Thus, this group is 
highly heterogeneous and one report suggest is should be further divided into 6 additional 
subtypes (159). 
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Treatment of advanced TNBCs 
Systemic therapies for the treatment of breast cancer is given in either the adjuvant 
setting (after primary therapy i.e. surgery) or neoadjuvant setting (before primary 
therapy) (160, 161).  Due to the aggressive nature of TNBCs neoadjuvant chemotherapy 
is increasing in frequency.  Further, recent evidence has suggested that TNBC patients 
tend to achieve better response to chemotherapy in the neoadjuvant setting relative to 
luminal breast cancers with regard to pathologic complete response (pCR)(162).  
However, following neoadjuvant therapy in TNBC patients those who did not initially 
achieve pCR had an overall worse overall survival than those with luminal subtypes (163, 
164).  This discrepancy between initial response rates of TNBCs in the neoadjuvant 
setting has been termed the “Triple Negative Paradox”. The implication of the CSC 
model (Fig 1.) suggests that in the patients that did not respond it is possible that the 
system therapy was able to only reduce bulk tumor volume, allowing CSCs to produce a 
rapid relapse at primary and metastatic sites.  In order to overcome this potential problem 
it may be necessary to combine conventional chemotherapy with a compound capable of 
selectively inhibiting CSCs.   
Treatment of Trastuzumab Resistant Breast Cancers 
The ERBB family of receptors (EGFR, HER2, HER3 and HER4) is characterized as 
transmembrane proteins which dimerise to elicit downstream signaling(165).  Of these 
receptors only HER2 lacks a ligand for activation and canonically signals through 
activation of PI3K and further downstream to AKT.  Four major targeted therapies are 
clinically used for the treatment of HER2+ breast cancers (166).  First and foremost is 
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trastuzumab which is an antibody capable of binding HER2 to inhibit downstream signal 
transduction.  As a first line therapy trastuzumab may be combined with a second 
targeted therapy known as pertuzumab.  Like trastuzumab, pertuzumab is an antibody 
which targets the extracellular domain of HER2, although it primarily functions by 
preventing ERBB family dimerization.  HER2+ breast cancers may also be treated in 
second line therapy by the use of ado-trastuzumab emtansine (T-DM1), which consists of 
the monoclonal antibody trastuzumab conjugated to the cytotoxic agent DM1 which 
inhibits of tubulin(167).  Finally, small molecule lapatinib may also be employed for 
HER2 targeted therapy as it is a reversible small molecule tyrosine kinase inhibitor 
effecting both HER2 and EGFR.  Unfortunately, while these four targeted therapies exist 
no cure is available for the treatment of metastatic HER2+ breast cancer.  Further, in one 
clinical trial less than 30% of metastatic HER2+ breast cancer patients initially responded 
to single agent trastuzumab and patients who respond to trastuzumab initially are likely to 
develop acquired resistance within 1-2 years(168, 169).  Therefore, it is necessary to 
identify new strategies for the treatment of HER2+ breast cancer patients after 
trastuzumab resistance develops.  Recently our collaborators have demonstrated that 
within PTEN deficient HER2+ breast cancers the generation of trastuzumab resistance 
leads to the induction of the epithelial to mesenchymal transition (EMT) and expansion 
of CSCs by activation of an IL-6/NF-kB positive feedback loop.  Therefore, in order to 
treat trastuzumab resistant breast cancers it may be advantageous to inhibit NF-kB 
signaling to inhibit both bulk tumor volume and eradicate CSCs.   
Using Sulforphane for the treatment of TNBCs and Trastuzumab Resistant Breast 
Cancers 
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As mentioned above, our laboratory has identified that the natural product sulforaphane 
(SF) is capable of inhibiting breast CSCs at concentrations well below its respective IC50 
in bulk cell lines (20).  While these results were attributed to inhibition of Akt/β-catenin 
signaling, a variety of different signaling pathways have been proposed for the bioactivity 
of SF (170).  However, accumulating literature across several types of cancers suggests 
that SF may be capable of reducing the function of NF-kB in multiple malignancies 
including leukemia, breast, and pancreatic cancer (171-173).  In addition to the role of 
NF-kB in regulating CSCs and trastuzumab resistance as mentioned above, this signaling 
node and the cytokines it produces have been reported to regulate TNBCs (174, 175).  
Docetaxel, a front line neo-adjuvant cytotoxic agent for the treatment of TNBCs, has 
been shown to increase circuiting cytokines which are produced from, and may further 
activate, NF-kB in breast CSCs (176).   Taken together this suggests that blockade of NF-
kB signaling lead to inhibition of breast CSCs, TNBCs, and trastuzumab resistant breast 
cancers.  Therefore, we hypothesize that SF will prevent docetaxel mediated cytokine 
production to provide clinical benefit to TNBC patients, as well as, disrupt the positive 
feedback loop driving trastuzumab resistant breast cancers to create a novel therapeutic 
option.   
In order to evaluate this hypothesis we propose the following specific aims: 
Specific Aims 
Aim 1 To combine docetaxel with sulforaphane for elimination of both bulk tumors and 
CSCs in TNBC 
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Objectives: A) To demonstrate that docetaxel expands breast CSCs by upregulation of 
IL-6 in TNBC cell lines in vitro and in vivo.  B)  To identify that sulforaphane 
preferentially inhibits TNBCs and their CSCs by inhibiting NF-kB signal transduction in 
vitro and in vivo.  C)  To demonstrate that the combination of docetaxel and sulforaphane 
suppresses both bulk cell line proliferation and CSCs in vitro and in vivo.   
Aim 2 To identify the efficacy of sulforaphane over the course of trastuzumab resistance 
in PTEN- breast cancers 
Objectives:  A) To evaluate changes in bulk cell line phenotype and signal transduction 
pathways following the generation of trastuzumab resistance in PTEN- cells.  B)  To 
demonstrate increased NF-kB activity and IL-6 expression following trastuzumab 
resistance can be inhibited by SF.  C) To evaluate the efficacy of SF to inhibit bulk cell 
line proliferation and CSCs within trastuzumab resistant breast cancers with PTEN in 
activation in vitro and in vivo. 
Aim 3 To determine additional potential mechanism of action of SF in trastuzumab 
resistant breast cancers with PTEN inactivation 
Objectives:  A) To use unbiased global mRNA expression analysis to determine 
alterations in signal transduction between trastuzumab sensitive and resistant cell lines.  
B)  To identify novel genes which are inhibited by SF preferentially with trastuzumab 
resistant cells.  C)  To validate the functional relevance of the gene target in trastuzumab 
resistant breast cancers with PTEN inactivation.   
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Figure 1.1 Therapeutic implications of the cancer stem cell model.  Normal stem or 
progenitor cells give rise to CSCs through deregulation or regained self-renewal capacity.  
CSCs are then capable of self-renewal and differentiation to form tumors, which left 
untreated can form new metastasis.  Conventional therapy will eliminate the bulk of the 
tumor mass leaving behind CSCs that then initiate recurrence and dislodge, spreading to 
distant organs.  Given a CSC inhibitor tumors will lose the ability for sustained growth 
and metastasis.  In combination with conventional therapy this will likely lead to disease-
free survival. 
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Figure 1.2 Critical signal transduction pathways essential for CSC function. Wnt 
signaling in stem cells is initiated by binding of Wnt to its receptor frizzled, ultimately 
leading to translocation of β-catenin to initial transcription.  Similarly, binding of the Hh 
ligands to Ptc relieves inhibition of the Gli family of transcription factor.  Extracellular 
ligands on neighboring cells activate the Notch pathway, causing cleavage of the NICD 
which translocate to the nucleus.  Interaction of inflammatory cytokines or endogenous 
receptors such as HER2 activates the key signaling nodes Akt and NF-κB.  Post-
translational modification of Akt and GSK-3β represent the generation of proteins 
capable of modulating multiple pathways including Wnt and Hh.  
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Figure 1.3 Natural products with demonstrated efficacy toward modulating targets 
critical to CSC function.  Successful inhibition of Wnt signaling has been shown using 
the compounds piperine and salinomycin.  The SMO antagonist cyclopamine prevents 
activation of the Hedgehog pathway, which is critical for the differentiation process.  
Inhibitors of the juxtacrine Notch signaling pathway include resveratrol and celastrol.  
Multiple pathways are targeted by the natural product sulforaphane, through inhibition of 
the molecular chaperone HSP-90 and the Akt signaling node.  Interactions of CSCs with 
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the surrounding microenvironment may be modulated by both parthenolide and 
echinomycin.   
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Chapter 2 
Combination of Docetaxel with Sulforaphane Synergistically Inhibits Triple 
Negative Breast Cancer and Cancer Stem Cells 
Abstract 
Triple negative breast cancer (TNBC) (ER-, PR-, Her2-), constituting 10-20% of all 
breast cancers, is a heterogeneous disease that has limited treatment options, exhibits 
rapid progression, and results in overall poor patient prognosis.  The cancer stem cell 
(CSC) model provides an attractive explanation for relapse of TNBC after primary 
therapy since these cells demonstrate resistance to conventional chemotherapy and are 
thought to be responsible for tumor relapse and metastasis.  Docetaxel is a commonly 
utilized therapeutic for the treatment of metastatic TNBCs, although no cure is ultimately 
available for these patients.  While docetaxel has been demonstrated to effectively reduce 
tumor volume accumulating evidences suggests it may fail to eliminate CSCs, possibly 
due to enhanced intratumoral cytokine expression.  Expressions of several cytokines, 
including IL-6, have been shown to regulate CSCs, and their own expression is 
determined in part by the activity of the NF-kB transcription factor.  Therefore, we 
propose that combination therapy with docetaxel and a CSC inhibitor capable of 
inhibiting NF-kB would be ideally suited for the treatment of TNBC patients receiving 
chemotherapy.  Our in vitro results demonstrate that docetaxel treatment increases the 
proportion of ALDH+ and CD44+/CD24-/EpCAM+ breast CSCs in TNBC cell lines.  
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Further, we identify that the natural product sulforaphane is capable of preferentially 
inhibiting breast CSCs and TNBCs in general by reducing NF-kB function in vitro.  
Addition of sulforaphane to docetaxel treatment potentiates its therapeutic effect in bulk 
cells lines.  This combination is also able to effectively eliminate breast CSCs in vitro 
through sulforaphane-mediated inhibition of IL-6, as evident by flow cytometry analysis, 
mammosphere formation, and reduced IL-6 secretion.  Using an orthotopic mouse 
xenograft model we demonstrate that docetaxel significantly reduces bulk tumor growth 
while increasing CSC frequency.  Conversely, sulforaphane (SF) treatment modestly 
inhibits bulk tumor volume but reveals a potent reduction in CSCs.  In vivo, the 
combination of docetaxel and SF exhibits a greater reduction in primary tumor volume 
and breast CSCs relative to either treatment alone.  These results suggest that SF-
mediated inhibition of breast CSCs and IL-6 provide a scientific rationale for using this 
agent in combination with docetaxel for the treatment of TNBC patients.   
Introduction  
Triple negative breast cancers (TNBCs) (ER-, PR-, Her2-), which represent the vast 
majority of basal and claudin-low subtypes, are an aggressive form of breast cancer with 
limited treatment options and poor prognosis in contrast to the other three types of breast 
cancers (luminal A, B, Her2+) (1-4).  The use of neoadjuvant chemotherapy has 
increased in recent years with several clinical trials demonstrating more frequent 
pathologic complete responses (pCR) in TNBC patients relative to other subtypes (5-8).  
Therapies in the neoadjuvant setting typically consist of a taxane, paclitaxel or docetaxel, 
with other chemotherapeutic agents such as anthracyclines or cyclophosphamide (9).  
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However, with respect to patients who do not exhibit pCR, overall survival is often worse 
in TNBC patients relative to non-TNBC patients due in part to higher rates of metastasis 
(6).  Strikingly, in advanced TNBC the duration of response to first line palliative 
chemotherapy has been reported to be less than 12 weeks and the response to secondary 
and tertiary therapies even shorter (9 and 4 weeks, respectively) (10).  
While considerable effort has been given to identify new therapeutic targets or prognostic 
markers which may predict response to chemotherapy in TNBC, an obvious strategy for 
treating these patients is not clear and is due largely to the heterogeneity of the subtype 
(11-14).  The breast cancer stem cell (BCSC) model provides an attractive explanation 
for the relapse of TNBC after primary chemotherapy (15-17).   This small population of 
BCSCs in tumors exhibits two key properties; self-renewal, which allows for long term 
proliferation potential, and differentiation to form the heterogeneous tumor bulk (18-24).  
With these properties BCSCs are thought to be responsible for tumor initiation and 
metastasis, and their relative abundance is correlated with poor patient survival (23, 25-
28).  In addition, these cells are have been shown to rely on alternative signal 
transduction pathways relative to their more differentiated counterparts, including Wnt/β-
catenin, Sonic Hedgehog (SHH), Notch, PTEN/AKT, and NF-kB (29-33). Due to several 
reported resistance mechanisms the efficacy of cytotoxic chemotherapy in BCSCs may 
be reduced, thereby allowing residual BCSCs within a TNBC patient to repopulate 
primary and metastatic tumors following neoadjuvant therapy.   
Docetaxel is commonly prescribed to TNBC patients and has established efficacy toward 
reducing tumor volume in preclinical and clinical settings.  However, several reports in a 
preclinical setting suggest that this therapy may actually fail to inhibit or even increase 
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the frequency of BCSCs (34-36).  In addition, docetaxel had been demonstrated to 
increase production of IL-6 and IL8 in patients (37).  Direct stimulation of breast cancer 
cell lines in vitro with IL-6 and IL-8 has been shown to increase BCSCs (35, 36, 38). 
Production of these cytokines is regulated by the activity of the transcription factor NF-
kB, which has been demonstrated to be of critical importance in the regulation of BCSCs 
(33, 39, 40).  Therefore, we hypothesize that the combination of docetaxel with a BCSC 
inhibitor capable of NF-kB inhibition would be ideally suited for therapy in TNBC 
patients. 
In this report we demonstrate that docetaxel treatment increases the proportion of BCSCs 
and enhances IL-6 production in TNBC cell lines.  Conversely, the natural product 
sulforaphane, which is capable of preferentially inhibiting TNBCs and ALDH+ BCSCs, 
reduces production of IL-6 through inhibition of NF-kB nuclear translocation and 
transcriptional activity.  Combination of these therapeutics not only elicits a synergistic 
response in bulk cell lines but SF suppresses docetaxel-mediated IL-6 production and 
BCSC expansion in vitro.  Finally, using an orthotopic mouse xenograft model with 
extreme limiting dilution analysis (ELDA) of serially reimplanted tumors, we 
demonstrate that docetaxel increases BCSCs while the combination of SF and docetaxel 
demonstrates greater efficacy in primary tumors and reduces BCSC frequency. These 
results provide a strong rationale for future studies aimed to utilize novel combination 
therapies for the treatment of TNBC patients.     
Results 
Docetaxel increases IL-6 expression and expands breast cancer stem cells in TNBC 
cell lines. 
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The role of IL-6 expression with regard to expanding the breast cancer stem cell 
population in vitro has been shown in many breast cancer cell lines (36, 38, 41, 42).  In 
addition, previous clinical trials have demonstrated that administration of taxanes 
(paclitaxel and docetaxel) to patients increases IL-6 in circulation (37); however, it is 
unknown if this circulating IL-6 is due primarily to secretion from cancerous cells or 
normal tissues.  In order to evaluate in vitro if these two phenomena are linked, we 
treated TNBC cell lines in vitro with docetaxel at increasing concentrations.  Following 
72 hour incubation with SUM149 (Basal) and SUM159 (Claudin-low) cells, the MTS 
proliferation assay was performed to identify the sensitivity of either cell line to 
docetaxel.  The efficacy of docetaxel was more pronounced in SUM149, with an IC50 of 
0.5 nM, relative to SUM159, which exhibited an IC50 of 3 nM (Fig 2.1 A).  In addition, 
the maximum effect at the highest dose tested was greater in SUM149 cells (89.5% vs 
76% at 100 nM).  At therapeutic concentrations which inhibited greater than 50% of bulk 
cell lines docetaxel increased the percentage of cells expressing BCSC markers 
CD44+/CD24-/Epcam+, as evident by FACS analysis, with maximum fold changes 
observed at 3.7 (5 nM) in SUM149 and 8.2 in SUM159 (Fig 2.1 B top and C).  In 
addition, in SUM149 72 hour treatment with docetaxel increased cells expressing the 
BCSC marker ALDH by 2.7 fold (Fig 2.1B bottom).  This suggests that BCSCs exhibit 
enhanced docetaxel resistance relative to non-BCSCs.  Next we sought to demonstrate a 
link between BCSC expansion and IL-6 secretion.  We treated SUM149 cells with the 
same concentrations that expanded BCSCs but for only 8 hours, replaced the medium, 
and performed ELISA to quantify the secretion of IL-6 after an additional 64 hours (Fig 
2.1C).   These results show a maximum of 9.2 fold increase in IL-6 secreted into the cell 
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culture medium relative to control treated cells with minimal alterations in cell viability.  
This suggests that release of IL-6 to expand BCSCs is a response of the tumor to external 
therapies.   
Sulforaphane preferentially inhibits TNBC cell lines and ALDH+ breast cancer 
stem cells in vitro. 
The anticancer efficacy of sulforaphane has been studied in many types of cancer (43-
49). However, most of these studies showed that sulforaphane only exhibits modest 
inhibition of bulk cancer cell lines at relatively high concentrations. Further, it is 
unknown if different subtypes of a given cancer will demonstrate varying responses to 
sulforaphane.  To identify if SF exhibits differential efficacy based on breast cancer 
subtype, the effect of SF on in vitro proliferation of 10 different breast cancer cell lines 
was carried out by MTS assay.  In the triple negative cell lines SUM149, SUM159, 
MDA-MB-231, and MDA-MB436 sulforaphane exhibits the lowest predicted IC50s, 
ranging from 7.63 to 10.63 μM, and produces a high predicted maximum effect (Fig. 
2.2A).  In luminal cell lines, which express the estrogen and/or progesterone receptors, 
SF sensitivity is decreased, as demonstrated by higher IC50 values of 14.5 μM for MCF7 
and 27.46 μM for ZR-75-1 cells (Fig. 2.2B).  In contrast to TNBC cell lines the HER2 
amplified cell lines SKBR3 and BT474 demonstrate the lowest efficacy, even at 
concentrations of sulforaphane up to 50 μM (Fig. 2.2C).  Interestingly, while MDA-MB-
453 and MDA-MB-361 cells have previously been shown to express HER2 the efficacy 
of SF in these cells is similar to that of the TNBC cell lines (Fig 2.2D), with IC50s of 
9.14 and 16.15 μM respectively. MDA-MB-361 contains an activating mutation in the 
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PIK3CA gene; in addition to this mutation, MDA-MB-453 has reduced PTEN activity 
(50).  It has previously been shown that expression of HER2 with activation of the AKT 
signaling pathway by PTEN deletion or PI3K activation results in cross talk, ultimately 
simulating the NF-κB signaling node (36, 51). 
Our laboratory has previously demonstrated that within the SUM159 cell line ALDH+ 
BCSCs show enhanced sensitivity to SF compared to bulk cells (the opposite of 
docetaxel efficacy) (43).  In order to evaluate this in additional breast cancer cell lines 
(SUM149 TNBC, ZR75-1 Luminal) we performed the Aldefluor assay after 72 hours of 
SF treatment.  FACS analysis shows similar results to those previously published, with a 
2-fold reduction in the percent of ALDH+ BCSCs with as little as 1 μM SF in SUM149 
cells (Fig 2.2E, bars).  SF reduces not only the percentage of residual BCSCs but also the 
absolute number of cells in this population at a concentration >7–fold lower than the bulk 
cell line IC50 (Fig 2.2E, line).  Additionally, Aldefluor analysis in luminal ZR-75-1 cells 
shows a significant reduction in ALDH+ BCSCs following 5 and 10 μM SF treatment.  
Again, inhibition of ALDH+ cells occurs at a >5-fold lower concentration relative to bulk 
cell line IC50.  These results confirm that SF is capable of preferentially reducing BCSCs 
across multiple subtypes of breast cancer, although the exact concentration may be 
dependent on the relative sensitivity of the bulk cell line to SF.    
Sulforaphane reduces NF-kB nuclear translocation and transcriptional activity. 
Reports of potential mechanisms of action for SF vary greatly between cancer cell lines 
derived from different organs of origin as well as within those derived from the same 
tissue but of different molecular subtype.  One potential theme emerging from the 
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literature is the function of SF to inhibit NF-κB signaling across various forms of cancer.  
Inhibition of NF-κB signaling is known to induce apoptosis in primitive AML CSCs 
(CD34+) but not in the same population of normal cord blood cells (52).  Further, this 
signaling node has been implicated in the formation of mammospheres and the 
production of cytokines which regulate BCSCs (53). The growth of triple-negative breast 
cancer (TNBC) cell lines has also been shown to rely on autocrine expression of IL-6 and 
IL-8, which are regulated by NF-κB (54, 55).  With SF able to preferentially regulate 
TNBCs, and the BCSCs within them, we sought to determine if NF-KB inhibition is 
responsible for its efficacy.   
Canonical activation of the NF-kB transcription factor is accomplished by a signal which 
results in translocation of the NF-kB subunits from the cytoplasm to the nucleus after 
dissociating from its endogenous inhibitor IκB.  In order to elucidate if SF is able to 
prevent this translocation SUM159 cells were incubated with increasing concentrations of 
SF, followed by stimulation with TNF-α.  The absence of SF and presence of TNF-α 
causes the NF-kB p65 subunit to translocate into the nucleus of SUM159 cells (Fig 2.3A, 
left two columns).  The addition of SF results in reduced nuclear NF-kB p-65 staining 
two hours after TNF-α addition (Fig 2.3 A, right columns).  In order to determine if 
blockade of translocation by sulforaphane translates to inhibition of transcriptional 
activity, TNBC cells (SUM159, MDA-MB-231) were stably transfected with a reporter 
construct which produces luciferase mediated by a NF-kB response element.  Following 
stimulation of transcription by TNF-α for six hours in the presence of increasing 
concentrations of SF, luciferase activity was determined (Fig 2.3B).  Stimulation with 
TNF-α in SUM159 and MDA-MB-231 cells results in a 4.0 and 4.4 fold increase in 
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luciferase activity, respectively, which was reduced in a dose-dependent manner by SF.  
This increase of NF-kB activity by TNF-α is not only completely repressed by SF in both 
cell lines, but in the case of 10 and 15 μM in SUM159 cells SF reduced luciferase activity 
relative to unstimulated levels in SUM 159 (10 μM p=0.011, 15 μM p=0.0002).  With 
this observation we sought to determine if SF would reduce endogenous NF-kB targets 
within the parental cell line in the absence of any stimulator factor.  Consequently, 
SUM159 cells were treated with concentrations of SF for 72 hours and the levels of 
secreted IL-6 and IL-8 were determined by ELISA (Fig. 2.3C).  Interestingly, SF reduces 
IL-6 expression at concentrations as low as 1 μM, which is sufficient to only inhibit 
BCSCs in terms of therapeutic efficacy. A maximum total inhibition of 68% is observed.  
SF reduces IL-8 by a maximum of 74%, albeit at a concentration which inhibits bulk cell 
line proliferation.  Taken together, these results suggest that SF is capable of reducing 
NF-kB function at therapeutically relevant concentrations in TNBCs, with IL-6 
suppression correlated with BCSC inhibition.   
Combination of Sulforaphane and Docetaxel synergistically inhibit bulk TNBC cell 
lines. 
The major benefit of combining docetaxel with sulforaphane is a rational combination of 
drugs to inhibit multiple cell populations within a heterogeneous tumor, both BCSCs and 
differentiated cells.  Another potential benefit is that the combination may be more 
effective than either drug alone (either additive or synergistic) within a given cell line.  
These scenarios allow for a reduction in doses while achieving the same therapeutic 
effect.  However, combination therapy may also produce an antagonistic relationship 
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which could potentially limit therapeutic efficacy.  In order to explore the potential of SF 
and docetaxel to enhance or reduce the efficacy of one another we first utilize a broad 
range of concentration combinations for either drug.  Then we apply the combination 
index (CI) theorem, developed by Chou and Talalay, based on the Median-Effect 
Equation (56).  Using this theorem, generally accepted values for CI indicate the 
relationship as follows: 0-0.9 is synergistic, 0.9–1.1 is additive, and CI values from 1.1 to 
infinity are antagonistic (57).  
As previously demonstrated, the therapeutic efficacy of docetaxel varies between the 
TNBC cell lines SUM149 and SUM159 (Fig 2.1A, IC50 0.5 vs 3 nM, respectively).  
However, the variability of these cell lines to SF is very slight (Fig 2.2A, IC50 7.4 vs 7.8 
μM, respectively).  Therefore, we sought to determine the therapeutic efficacy of 
different combinations of SF and docetaxel concentration by the MTS proliferation assay 
in both cell lines.  The SUM159 cell line was treated for 72 hours with increasing 
concentrations of docetaxel (0, 0.1, 0.5, 1, 5, 1, and 100 nM) alone or with fixed 
concentrations of SF (Fig 2.4A, left).  Addition of 5 μM SF was sufficient to 
synergistically inhibit bulk cell line growth at all but the highest concentration of 
docetaxel, which reduced viability to 70%.  Automated analysis of CI values was 
performed using Compusyn (ComboSyn, Inc.) and revealed that all of the tested 
combined doses (36 total), which ultimately inhibit 50% of cells, experience a synergistic 
effect (Fig 2.4A, right).   Interestingly, in SUM149  cells many of concentration 
combinations of docetaxel with SF led to an additive effect at 1 nM docetaxel and below 
(Fig 2.4B), while concentrations of docetaxel above its IC50 (red symbols) resulted in a 
strong antagonistic response in the bulk cell line (Fig 2.4B, right).  These results suggest 
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that if the goal of future studies is aimed at synergistically inhibiting bulk tumor volume 
then optimizing dose regimens may be critically important.    
Combination of Sulforaphane and Docetaxel inhibits BCSCs in vitro and reduces 
IL-6 expression. 
In order to effectively eliminate breast cancers it is necessary to eliminate the BCSCs 
which are responsible for tumor initiation, recurrence, and metastasis.  As demonstrated 
above, SF and docetaxel elicit the opposite effect in BCSCs: SF inhibits but docetaxel 
increases the percentage of this population.  However, it is unknown if the inhibitory 
effect of SF is sufficient to overcome BCSC expansion by docetaxel.  Consequently, we 
performed the Aldefluor assay in vitro to monitor the relative levels of ALDH+ BCSCs 
in the TNBC cell line SUM149 following treatment with SF and docetaxel alone or in 
combination (Fig 2.5A).  Consistent with previous results (Fig 2.1C), 5 nM docetaxel 
alone increases the percentage of ALDH+ BCSCs by 71% following 72 hour treatment.  
Conversely, 2.5 μM SF alone is capable of reducing this population 2 fold, consistent 
with previous results (Fig 2.2E).  Strikingly, the combination of 2.5 μM SF with 5 nM 
docetaxel not only prevents BCSC expansion but actually reduces the population to the 
same extent as SF treatment alone.   This effect from combination is also observed with 
10 nM docetaxel treatment which, taken with results from Figure 2.1C, suggests SF 
inhibition of the ALDH+ BCSCs is likely to occur to the same extent regardless of 
docetaxel concentration.   
To further support our findings, we performed an additional functional assay to determine 
the effect of treatment on BCSCs.  Normal breast stem and progenitor cells, and their 
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cancerous counterparts, possess a unique ability of being resistant to anoikis (58).  
Therefore, when a heterogeneous population of breast-derived cells is placed into serum 
free and non-adherent conditions, the majority of cells will undergo a programmed cell 
death.  This leaves only the stem and progenitor cells able to proliferate, generating free 
floating spheres referred to as mammospheres.  By evaluating the effect of treatment on 
the frequency of cells in parental cell lines capable of forming these spheres and also the 
sphere size, we can infer if a drug is inhibiting stem and progenitor cells.  Further, by 
collecting primary treated cells and passaging for another generation grown in the 
absence of drug, it is possible to determine if long term self-renewal of these populations 
is altered.  In the presence of 1 nM docetaxel, the primary sphere formation rate is 
unaltered (Fig 2.5B, bars) relative to the vehicle treated control cells; however upon 
passaging in the absence of additional drug treatment, more secondary spheres form (Fig 
2.5B, line).  Conversely, 2.5 μM SF and the combination of 2.5 μM SF with 1 nM 
docetaxel both inhibit primary sphere formation and alter the long term self-renewal of 
BCSCs and progenitors, as evident by decreasing the ability to form secondary spheres.  
For all drug treatments, the size of spheres is reduced relative to control (Fig 2.5B, 
Bottom).   
Due to the observed increase in BCSCs by docetaxel and decrease by SF and their 
respective regulation of NF-kB signaling, we hypothesize that SF was preventing 
docetaxel-mediated IL-6 production.  In order to test this hypothesis SUM149 cells were 
cultured in the presence of docetaxel, SF, or different combinations of the two as 
previously described (Fig 2.1D and Fig 2.3C).  In line with our previous experiments 2.5 
μM SF reduces IL-6 protein secretion 2-fold whereas docetaxel increases IL-6 secretion 
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3.5-fold, as measured by ELISA (Fig 2.5C, white bars).  Further, the addition of 1, 2.5, 
and 5 μM SF is sufficient to abrogate IL-6 production induced by docetaxel (Fig 2.5C, 
red bars).  These results suggest that a low dose sulforaphane in combination with 
therapeutically relevant concentrations of docetaxel effectively eliminates BCSCs by 
preventing NF-kB signal transduction.   
Combination of Sulforaphane and Docetaxel significantly inhibit tumor growth and 
BCSCs in vivo. 
Elimination of BCSCs is critical to ultimately curing patients.   It is also necessary to 
eliminate the more differentiated cells, which are responsible for the majority of a 
tumor’s volume, in order to reduce symptoms of disease progression.  Further, due to the 
genetically unstable nature of cancer cells it is possible that overtime a more 
differentiated cell could acquire mutations or experience enough environmental or 
stochastic influence to reactivate genes responsible for self-renewal.  These potential 
problems could then lead to the acquisition of BCSC characteristics and little would be 
done to eliminate the disease.  Accordingly, we sought to evaluate the ability of SF and 
docetaxel combination treatment to inhibit bulk tumor volume and BCSCs.   We utilized 
an advanced treatment orthotopic mouse xenograft model and performed extreme 
limiting dilution analysis (ELDA) in secondary mice using residual primary tumors (59).   
After implantation of 1.5 million SUM149 cells into the fourth mammary pad of 
NOD/SCID mice, tumors were allowed to reach an average volume of 50 mm
3
 before 
randomizing the mice into four separate treatment groups (Fig 2.6A).  Treatments 
included 0.9% saline (control), 50 mg/kg SF daily, 10 mg/kg docetaxel weekly, and 50 
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mg/kg SF daily with 10 mg/kg docetaxel weekly.  All treatments were administered via 
intraparitoneal (I.P.) injection.  Treatment efficacy on primary tumor volume was 
evaluated when control tumors reached the protocol specific endpoint.  Our data show 
that SF treatment reduces bulk tumor volume by 37.4% (p=0.011), while docetaxel and 
the combination reduce tumor volume by 83.2% and 92.5%, respectively.  Interestingly, 
only the combination of SF and Docetaxel cause significant (p=0.039) tumor regression 
relative to the maximum tumor volume for that treatment group (day 27 vs 51).  Mouse 
body weight was consistent throughout the course of study, demonstrating no obvious 
toxicity at the indicated dose regimens (Fig 2.6B).   
In order to evaluate the therapeutic efficacy of the given treatment groups with respect to 
BCSCs, primary tumors were harvested and dissociated into a single cell suspension to 
obtain residual live human cells (DAPI-, H2KD-) with FACS.  Three separate dilutions 
of cells from each treatment group were implanted into recipient secondary mice, which 
had not received any therapy, to quantify the frequency of tumor initiating BCSCs by 
ELDA (Fig 2.6C).  After 7 weeks tumor formation rates demonstrate that one in 1514 
control-treated cells was capable of tumor initiation.  Docetaxel significantly increased 
this frequency to one in 330 cells, whereas both SF and combination therapy reduced the 
number of tumor initiating cells (one in 3181 and one in 4245 cells, respectively).  Taken 
together, these in vivo results suggest that the combination of SF and docetaxel is the 
most effective treatment to reduce both bulk tumor volume and the BCSC population.          
Discussion 
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Treatment options for breast cancer vary depending on the subtype.  Luminal A (ER or 
PR+, Her2-) and luminal B (ER or PR+, Her2-, Ki-67 high or ER-PR+, Her2+) breast 
cancers have multiple treatment options, including endocrine, anti-HER2, and 
conventional cytotoxic chemotherapy. Her2+ (ER and PR-, Her2+) breast cancers may 
respond well to anti-HER2 therapy in combination with cytotoxic chemo-therapy (60). 
However, triple negative breast cancers (TNBC) (ER-, PR-, Her2-), which represent the 
vast majority of basal and claudin-low subtypes, are resistant to most current treatment 
options and are largely restricted to treatment with conventional cytotoxic chemotherapy 
(61).  The preclinical methods and clinical trial endpoints by which these compounds are 
evaluated tend to be focused on reducing tumor volume to delaying disease progression.  
With these endpoints, it is possible that conventional therapies only reduce bulk tumor 
volume and fail to eliminate the BCSCs which may make up only a small portion of the 
heterogeneous tumor.   
In order to cure TNBCs there is a critical need to develop effective strategies that 
eliminate both BCSCs, responsible for metastasis and relapse after therapy, as well as the 
more differentiated cancer cells which may cause unwanted symptoms, particularly at 
metastatic sites. However, accumulating preclinical evidence suggest that many 
anticancer agents such as paclitaxel, sunitinib, doxorubicin, and gemcitabine only inhibit 
the growth of differentiated cancer cells but fail to eliminate or may even expand CSC 
populations (62-65). In this report we demonstrate that the conventional cytotoxic 
chemotherapy docetaxel, which inhibits microtubule polymerization to shrink bulk tumor 
volume, actually enhances IL-6 production, thereby increasing BCSCs.  This data is 
consistent with previous reports demonstrating that docetaxel increases IL-6 and IL8 
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production both in vitro and in patients and that direct stimulation with IL-6 and IL-8 has 
been shown to increase BCSCs (35-38). Production of both these cytokines is regulated 
by the activity of the transcription factor NF-kB, which has been demonstrated to be of 
critical importance in the regulation of CSCs (33, 39, 40, 52, 53). Furthermore, IL-6 is 
known to regulate NF-kB through STAT3, an interaction capable of establishing a 
positive feedback loop (36, 42).   
The anticancer efficacy of sulforaphane has been shown in a variety of cancers including 
those from breast, colon, leukemia, prostate, and pancreatic cell lines (66-69). However, 
in most cases the IC50 of this compound is above 5 μM and is reported with high 
variability depending upon the cell lines used.  Our group first reported that SF 
selectively inhibits self-renewal of BCSCs at relatively low concentrations (0.5-5 μM) 
relative to the bulk cell line IC50 (43). These results were subsequently confirmed by the 
Herr and Shankar groups, where it was demonstrated that SF eliminates pancreatic and 
prostate CSCs (69, 70).  In order to establish a greater understanding of SF efficacy, and 
how it varies among breast cancer subtypes, we demonstrate two key features of SF 
therapy.  First, TNBCs are the most sensitive subtype to SF treatment, with HER2+ 
breast cancers tending to be resistant.  Second, within a given cell line, the ALDH+ 
BCSCs are more sensitive than the heterogeneous bulk.  This information provides a 
rationale for further studies which seek to utilize SF treatment in breast cancer because it 
identifies a clear population of patients who are likely to consistently respond (TNBCs).  
A staggering number of potential mechanisms of action have reported to explain SF’s 
efficacy; regulation of Nrf2, HDAC, Chk2, p21, MAPK, death receptor, NF-kB, Stat3, 
and Hsp90 (44, 71, 72).  While SF may indeed regulate these molecules it is unclear what 
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their relative contributions are to efficacy and in what contexts each are relevant.  In this 
report we identify that SF inhibits NF-kB function by preventing intracellular 
translocation and transcriptional activity.  Noting that both BCSCs and TNBCs in general 
are more dependent on cytokine-NF-kB signaling and that we have shown SF 
preferentially inhibits all of these factors, we hypothesize that in TNBCs NF-kB 
inhibition is the major mechanism of action for efficacy.  This is consistent with the 
report by Kallifatidis et. al. demonstrating pancreatic cancer cell lines and their respective 
CSC population are sensitive to SF-mediated NF-kB inhibition (73).  
As identified above our results indicate that docetaxel treatment increases both ALDH+ 
and CD44+/CD24-/EpCAM+ BCSCs as well as IL-6, while SF inhibits BCSCs across 
multiple subtypes of breast cancer and also NF-kB.  Therefore we postulate that SF is 
well suited for combination with docetaxel to overcome induction of BCSCs through 
regulation of IL-6.  In vitro, therapeutically relevant doses in which docetaxel which 
would inhibit the majority of differentiated cells in combination with a low dose of SF 
capable of inhibiting BCSCs result in SF-mediated inhibition of IL-6 production.  
Consequently, not only does the combination block docetaxel-mediated CSC expansion 
but also actually reduces BCSC levels to that of SF treatment alone.   In bulk TNBC cell 
lines in vitro this combination leads to an additive (SUM149) or synergistic (SUM159) 
response when 50% of cells are inhibited, for instance when concentrations below the 
IC50 are used for both drugs.  However, when docetaxel concentrations well above the 
IC50 are combined with concentrations of SF near its IC50, an antagonist response is 
observed.  While this does not alter the conclusion that SF and docetaxel should be 
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combined to target both BCSCs and reduce bulk tumor volume, it does indicate that there 
may be a need for future studies to identify an optimum dosing regimen.   
Using an orthotopic mouse xenograft tumor model, I.P. administration of daily SF in 
combination with weekly docetaxel leads to a dramatic reduction in primary tumor 
growth and begins to cause tumor regression.  Furthermore, ELDA of secondary tumor 
formation with residual cells from the primary tumors illustrates that docetaxel indeed 
increases the BCSC frequency, whereas the combination treatment dramatically reduces 
it.  These results are similar to those reported by Herr’s research group in which the 
combination of SF with gemcitabine in pancreatic cancer reduced CSCs and enhanced 
gemcitabine-mediated cytotoxicity (69).  However, in our study no observable reductions 
in body weight occurred, even in the combination treatment group.  Taken together, these 
results demonstrate that treatment of TNBCs with cytotoxic chemotherapy would greatly 
benefit from the addition of SF to prevent expansion of and eliminate BCSCs.   
Material and methods  
Cell Lines and Reagents. SUM159 and SUM149 cell lines were cultured under a  5% 
CO2 environment in F12 medium (Invitrogen, Carlsbad, CA) supplemented with 5% fetal 
bovine serum (Fisher Scientific, Pittsburgh, PA), 1% antibiotic-antimycotic (Invitrogen, 
Carlsbad, CA), 5 µg/ml insulin (Sigma-Aldrich, St Louis, MO), 1 μg/ml hydrocortisone 
(Sigma-Aldrich, St Louis, MO), and 4 μg/ml gentamicin (Invitrogen, Carlsbad, CA).   
MCF-7 was maintained in RPMI-1640 supplemented with 10% fetal bovine serum, 1% 
antibiotic-antimycotic, and 5 µg/ml insulin.  HER2 amplified SKBR-3 and BT474 were 
cultured in DMEM supplemented with 10% fetal bovine serum and 1% antibiotic-
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antimycotic.  ZR75-1, MDA-MB-436, and MDA-MB-231 were cultured in RPMI-1640 
supplemented with 10% fetal bovine serum, and 1 % antibiotic-antimycotic  
MTS Cell Proliferation Assay.  Cell lines were seeded at a density of 3,000 cells per 
well in 96-well plates.  The following day wells were incubated with sulforaphane, 
docetaxel, or a combination of the two drugs at varying concentrations for a period of 72 
hours.  Reduction in proliferation relative to control-treated cells was determined by the 
MTS assay (Promega) according to manufacturer’s instruction.  Reduction of tetrazolium 
compound MTS into a soluble formazan product with absorbance at 490 nm is directly 
proportional to number of viable cells in culture.  Pharmacodynamic modeling was 
performed using WinNonlin (Pharsight) with a sigmoid inhibitory effect model which 
estimates baseline effect, maximum effect, EC50, and shape parameter Gamma.  In the 
case of treatment with both SF and docetaxel, calculation of the combination indices were 
automated using Compusyn (ComboSyn Inc.) software where a fit of r >0.95 was 
considered an accurate simulation of dose and effect.   
Flow Cytometry Analysis. Cell lines were plated at a density of 500,000 cells in 10 cm 
plates and allowed to adhere overnight.  Treatments with sulforaphane, docetaxel, or 
combination at various concentrations of both drugs were carried out for 72 hours.  
Following treatment adherent cells were collected, counted for determination of absolute 
cell numbers, and stained with CD44-APC (BD Biosciences), CD24-PE (BD 
Biosciences), and EpCAM-PE-CY7 (Biolegend) in HBSS with 2% FBS on ice for 45 
min.  The Aldefluor assay (STEMCELL Technologies) was carried out according to 
manufacturer’s instruction.  Incubation with ALDH substrate was performed for 45 min 
in a 37 °C water bath.  For each replicate within a given treatment group, a DEAB 
 58 
 
negative control was present to set a positive gate with a background positivity of 0.1%.  
After staining, cells were washed with 2% FBS in HBSS followed by addition of DAPI 
immediately before analysis to determine viability. 
Determination of secreted cytokines.  Cell lines were seeded at a density of 250,000 
cells in a 6-well plate and allowed to adhere overnight.  Treatment with docetaxel was 
performed in the presence or absence of SF for 8 hours.  Afterward cells were washed 
with PBS and resuspended in cell culture medium with or without SF.  After 72 hours 
media was collected, centrifuged, and 200 µl were subjected to an ELISA to determine 
secretion of human IL-6 and IL-8.  Assays were performed using paired antibody kits 
(Duosets, R&D Systems, Minneapolis, MN) according to manufacturer’s protocol with 
two exceptions:  samples were incubated overnight at 4 °C, and the blocking/assay buffer 
was 0.2% casein in tris-buffered saline.  Data was acquired with a BioTek Synergy HT 
plate reader and analyzed using Gen5 software (Winooski, VT). 
Immunocytochemistry.  SUM159 cells were seeded at a density of 20,000 cells per well 
in 4-well glass chambers slides (lab-tek) and allowed to adhere overnight.  Sulforaphane 
was incubated at the indicated concentration for 30 min, followed by the addition of 50 
ng/ml TNF-α for two hours.  Treated cells were fixed using ice cold 1:1 methanol to 
acetonitrile followed by blocking with 3% bovine serum albumin.  Primary incubation 
with anti-p65 NF-κB (Cell Signaling Technology) was carried out at 4 °C overnight, 
followed by incubation with Alexa Fluor 488-conjugated secondary antibody (Invitrogen) 
for two hours at room temperature.  Fluorescent imaging was carried out with a Nikon 
Eclipse TE2000-S microscope and photos were acquired using MetaMorph 7.6.0.0. 
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Luciferase Reporter Assay.  Lentiviral particles containing luciferase reporter construct 
driven by NF-κB (system biosciences) were obtained and transfected into SUM159 and 
MDA-MB-231 cell lines. Briefly, four copies of NF-κB TRE sequences 
"GGGACTTTCC" were inserted upstream of minimal essential CMV (mCMV) promoter 
which drives GFP-T2A-luciferase. Polyprotein is cleaved at the T2A site to give rise to 
GFP and Luciferase.  Cell lines were plated at a density of 2500 cells per well in a clear 
bottom, white 96-well plate and treated with the indicated concentration of SF.  Two 
hours following incubation with SF, the TNF-α concentration in media was brought to 50 
ng/ml. After six hours Luciferase activity was measured according to manufacturer’s 
instructions using oneGlo assay (promega) on a Bio-Tek Synergy 2 plate reader. 
Mammosphere Formation Assay. SUM149 cells were plated at a density of 2,000 cells 
per well in an ultra-low attachment 6 well plate (Corning).  Serum free medium consisted 
of MEBM base medium supplemented with 2% B27 (Invitrogen), 1% P/S (Invitrogen), 4 
ug/ml gentamicin (Invitrogen), 5 ug/ml insulin (Sigma-aldrich), 20 ng/ml EGF (Sigma-
aldrich), 20 ng/ml bFGF (Sigma-aldrich), 1 ug/ml hydrocortisone (Sigma-aldrich), and 
1:25,000,000 β-ME (Sigma-aldrich). Drug treatment with sulforaphane, docetaxel, or the 
combination of the two was carried out for seven days.  After drug treatment individual 
spheres were counted manually and representative images were acquired using a Nikon 
Eclipse TE2000-S microscope.  Generation of secondary spheres was carried out by 
collection of primary spheres using a nylon 40 µm mesh filter, followed by collection of 
single cells from spheres by trypsinization in conjunction with manual dissociation by 
passage through a 25 gauge needle.  A fixed number of live cells was then equally 
distributed into 96-well plates for each treatment group, and cultured for an additional 
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seven days in the absence of drug.  Secondary sphere formation rate was manually 
determined by counting the number of cells plated and total number of spheres formed. 
Advanced Tumor Model.  All studies involving mice were conducted in accordance 
with a standard animal protocol approved by the University Committee on the Use and 
Care of Animals at the University of Michigan.  Female five week old non-obese 
diabetic/severe combined immunodeficient (NOD/SCID) mice were obtained from 
Jackson Laboratory. Xenograft formation was generated by direct injection of 1.5 million 
SUM149 cells, suspended in 50 ul of 25% F-12 in matrigel, into the exposed no.4 
inguinal mammary pad.  Tumor detection was assessed by palpation and, once identified, 
measurement of tumor volume was carried out using digital calipers every five days.  
Sulforaphane (50 mg/kg daily), docetaxel (10 mg/kg once every seven days), or the 
combination of both were administered via I.P. injection beginning when tumor volume 
reached approximately 50 mm
3
.  When the combined sulforaphane and docetaxel 
treatment began to cause significant tumor regression mice were euthanized by CO2 
inhalation, tumors were isolated, and extreme limiting dilution analysis in secondary 
mice was performed. 
Extreme Limiting Dilution analysis.  Isolated primary tumors were mechanically 
dissociated using a gentleMACS octo tissue dissociator with C tubes (Miltenyi Biotec).  
In order to consistently obtain single cell suspensions a human tumor dissociation kit 
(Miltenyi Biotec) was used according to manufacturer’s instruction for “tough tumors.”  
Briefly, tumors were cut into 2-4 mm pieces and exposed to dissociation enzymes.  
Following incubation at 37 °C for 30 min on an orbital shaker, mechanical dissociation 
was carried out with the genteMACS and this process was repeated three times.  
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Dissociated cells were collected after passage through a 40 μm nylon mesh filter.  Live 
human cells from xenografts were obtained by FACS on a SY3200 (Sony Biotechnology) 
flow cytometer after selection of DAPI- and H2KD- cells. Secondary female, five week 
old NOD/SCID mice were inoculated with 10,000, 1,000, or 100 cells from each 
treatment group as described above.  Tumor formation rate in secondary mice was 
assessed by direct palpitation for seven weeks following cell implantation and used to 
assess BCSC frequency using the ELDA webtool 
(http://bioinf.wehi.edu.au/software/elda/).  
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Figure 2.1 Docetaxel reduces bulk cell line viability while increasing IL-6 expression 
and breast cancer stem cells.  (A) MTS proliferation assay performed in triple negative 
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breast cancer cell lines SUM149 and SUM159 in the presence of increasing 
concentrations of docetaxel (Doc) for 72 hours. N=6. (B)  SUM149 cells, which exhibit 
distinct populations CD44+/CD24-/EpCAM+ and ALDH+ breast cancer stem cells, 
cultured in the presence of increasing concentrations of docetaxel for 72 hours followed 
by antibody staining (top) or Aldefluor assay (bottom) as determined by FACS analysis.  
N=3.  (C)  FACS analysis of SUM159 cells treated with docetaxel for 72 hours followed 
by staining of CD44, CD24, and EpCAM.  N=3.  (D)  Concentration of secreted IL-6 
protein in media from 64 hour culture of SUM149 cells after being exposed to docetaxel 
for eight hours as determined by enzyme-linked immunosorbent assay. N=3. Data 
presented as average value ± standard deviation.  * P<0.05, # P<0.01.    
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Figure 2.2 Sulforaphane preferentially inhibits triple negative breast cancers and 
ALDH+ breast cancer stem cells.  MTS proliferation assay was carried out after 
incubating cell lines with increasing concentrations of sulforaphane (SF) for 72 hours. 
N=6 (A) Triple negative cell lines SUM149, SUM159, MDA-MB-231, and MDA-MB-
436 exhibit the highest maximum effect values and lowest IC50s. (B) Luminal cell lines 
MCF7 and ZR-75-1, containing estrogen and progesterone receptors, exhibit higher 
variability in efficacy. (C)  HER2 amplified SKBR3 and BT474 exhibit SF resistance (D) 
Luminal B MDA-MB-361 and MDA-MB-453, expressing HER2 and containing AKT 
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activating mutations, and are sensitive to SF.  (E) FACS analysis of the Aldefluor assay 
following 72 hour incubation of SUM149 or ZR-75-1 cells exposed to increasing 
concentrations of SF. N=3.  Data presented as average value ± standard deviation.  * 
P<0.05, # P<0.01. 
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Figure 2.3 Sulforaphane inhibits NF-kB nuclear translocation and transcriptional 
activity in triple negative breast cancers.  (A) Representative immunocytochemical 
staining of the SUM159 cell line for the p65 subunit of NF-kB after pre-incubation for 30 
min with increasing concentrations of SF with and without the addition of 50 ng/ml TNF-
α for 2 hours. Counter staining of nuclei was carried out with 1 µg/ml DAPI immediately 
before imaging (bottom). Red arrow indicates the cytoplasmic-nuclear boarder. Images 
obtained using a 40X objective. (B) TNBC cell lines SUM159 and MDA-MB-231 were 
transfected with a NF-kB-dependent luciferase reporter.  Cell lines were treated with 
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increasing concentrations of SF for 2 hours followed by the addition of 50 ng/ml TNF-α; 
six hours later luminescence was measured.  N=3.  (C) Concentration of secreted IL-6 
(left) and IL-8 (right) protein in media from 72 hour culture of SUM159 cells after being 
exposed to increasing concentrations of SF, as determined by enzyme-linked 
immunosorbent assay.  N=3. Data presented as average value ± standard deviation.  * 
P<0.05, # P<0.01.    
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Figure 2.4 Combination of docetaxel and sulforaphane cooperate to inhibit bulk cell 
line proliferation at specific concentrations.  MTS proliferation assay was performed in 
TNBC cell lines (A) SUM159 and (B) SUM149 cell viability following incubation with 
increasing concentrations of docetaxel alone or in combination with fixed concentrations 
of SF.  N=4.  Data presented as average value ± standard deviation. Calculations of 
combination index (CI) values versus fraction of cells inhibited (fa) were automated by 
inputting MTS results into Compusyn (Combosyn) software.  Typical interpretations of 
CI values for an additive effect range from 0.9-1.1 (A, right, blue lines), while <0.9 
suggests synergism and >1.1 indicates antagonism. 
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Figure 2.5 Sulforaphane prevents docetaxel-mediated IL-6 production and reduces 
BCSCs during combination treatment.  (A) FACS analysis of the Aldefluor assay 
following 72 hour incubation of SUM149 cells exposed to increasing sulforaphane (SF) 
and docetaxel (Doc) alone or in combination.  N=3.  (B) Percentage of cells from bulk 
SUM149 cell line which are capable of forming mammospheres when treated with SF 
and Doc alone or in combination.  Bars represent primary sphere formation and lines 
represent secondary generation which was not exposed to further drug treatment after 
passage.  N=3. A representative image of a sphere for each treatment group included 
below where and a 40X objective was used for image acquisition. (C) SUM149 cells 
were treated for eight hours in the presence of SF and Doc alone or in increasing 
combination of both drugs.  Cells were washed and media replaced with SF 
supplemented medium where indicated for an additional 64 hours before measurement of 
secreted IL-6.  N=3.  Data presented as average value ± standard deviation.  * P<0.05, # 
P<0.01.    
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Figure 2.6 Docetaxel and sulforaphane cooperate to eliminate both bulk tumor 
volume and BCSCs in vivo. (a) NOD/SCID mice bearing SUM149 xenografts with an 
average tumor volume of 50 mm
3
 were randomized into treatment groups which received 
daily 0.9% saline (Control), daily 50 mg/kg sulforaphane (SF), weekly 10 mg/kg 
docetaxel (Doc), or daily 50 mg/kg SF in combination with weekly 10 mg/kg Doc as a 
cassette dose.  Each drug was administered via I.P. injection.  Arrow denotes the 
beginning of treatment in primary mice. N=5. * p ≤ 0.05 in final tumor volume 
comparisons. (B) Body weight of mice receiving each treatment regimen over the course 
of administration. N=5. (C) Primary xenografts were removed, dissociated, and serially 
reimplanted into secondary mice allowing for calculation of tumor initiating CSC 
frequency by extreme limiting dilution analysis (ELDA).  The total number of tumors 
formed, the number of tumors implanted for each treatment group, and the dilutions of 
cells implanted used to calculate CSC frequency is shown (left).  Estimates of CSC 
frequency and the p-value associated with pairwise differences (right) was automated 
using the ELDA web resource.    
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Chapter 3 
Trastuzumab resistance induces EMT and transforms HER2
+
PTEN
-
 to a triple 
negative breast cancer that is susceptible to inhibition by sulforaphane 
Abstract   
Although the development of trastuzumab has made significant advances for HER2+ 
breast cancer treatment, the majority of patients develop trastuzumab resistance, in which 
40% patients have loss of PTEN function. However the consequence of continued use of 
trastuzumab in these patients predisposed to drug resistance is unknown. We demonstrate 
that trastuzumab resistance by long term treatment (LTT) in HER2+ breast cancer cells 
with PTEN inactivation (BT474 PTEN-LTT) induces characteristics of the epithelial-
mesenchymal transition (EMT), and transforms HER2+PTEN- breast cancer to triple 
negative phenotype.  In addition, these cells undergo a signaling shift from HER2/AKT 
dependency to activation of IL-6/STAT3/NF-κB positive feedback loop. Inhibition of IL-
6/NF-κB loop by sulforaphane (SF) suppresses IL-6 production, NF-κB translocation, 
and transcriptional activity.  The disruption of IL-6/NF-κB loop by sulforaphane leads to 
preferential inhibition of trastuzumab-resistant BT474 PTEN-LTT cells, while it showed 
minimal efficacy in trastuzumab-sensitive BT474. In advanced treatment xenograft 
models, SF inhibited tumor growth in mice bearing trastuzumab-resistant BT474 PTEN-
LTT tumors to the same extent as cytotoxic chemotherapy.  Importantly, SF reduced the 
frequency of breast cancer stem cells by 5.4-fold as shown by re-implantation assays.  In 
 76 
 
contrast, trastuzumab treatment increased the cancer stem cells population by 4.6-fold.  
This data suggest that continued use of trastuzumab in HER2+ tumors with PTEN 
inactivation may induce EMT, increase breast CSCs, and result in a subtype switch 
generating a TNBC through the IL-6/NF-κB signaling loop. Sulforaphane mediated 
inhibition of the IL-6/NF-κB signaling loop may provide a novel treatment strategy for 
trastuzumab-resistant breast cancers with PTEN deletion. 
Introduction 
The development of anti-HER2 targeted therapy (trastuzumab) has significantly 
improved the survival of HER2+ breast cancer patients.  However, initial response rates 
in women with HER2 overexpressing metastatic disease treated with single agent 
trastuzumab range from only 11.6-34 % (1, 2). Further, the majority of patients given 
trastuzumab treatment will develop drug resistance within one to two years (3, 4).  
Therefore, it is necessary to identify potential mechanisms of trastuzumab resistance and 
develop alternative therapeutics for trasutumab-resistant HER2+ breast cancers.  
Previous studies have revealed compensatory signaling mechanisms responsible for the 
drug resistance of HER2+ breast cancer, including: inactivation of PTEN tumor 
suppressor; antigen masking on HER2 epitope by MUC4; enhanced signaling through 
other ERBB family receptors; cross-talk of HER2 with IGF-1R; and mutational 
activation of downstream signaling through PI3-K/AKT pathway (5-9).   Inactivation of 
the PTEN tumor suppressor, found in ~40% of patients with HER2 overexpression, has 
been demonstrated to induce drug resistance in tumor xenografts and correlate with 
trastuzumab resistance in patients (10).   In addition, inactivation of PTEN has been 
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shown to be a crucial factor inducing epithelial to mesenchymal transition (EMT) in 
breast, colon, nasopharyngeal, and prostate cancers (11-14).  Furthermore,   Recent 
evidence suggests that EMT may activate diverse alternative survival pathways or  
actually transform the molecular subtype of the malignancy in castration/enzalutamide 
resistant prostate cancer, RAF inhibitor resistant melanoma, and EGFR inhibitor resistant 
lung cancer (15-18).   
Korkaya et.al. previously reported that drug resistance in HER2 overexpressing cell lines 
with PTEN deletion by long term culture with trastuzumab (LTT) induces characteristics 
of the EMT and expands the breast cancer stem cell (BCSC) population (19).  This 
induction of EMT and expansion of cancer stem cells is proposed to occur through 
activation of an IL-6/NF-κB positive feedback loop.  Interestingly, several studies have 
demonstrated that inflammatory cytokines such as IL-6 are upregulated in triple negative 
breast cancers (TNBC) and correlated with poor patient prognosis (20-23).   
In this study, we report that trastuzumab resistance in PTEN-deficient HER2+ breast 
cancer results in the epithelial to mesenchymal transition (EMT), as evident by reduced 
expression of epithelial markers and increased mesenchymal makers. Following EMT, 
trastuzumab resistant PTEN-deficient breast cancer cells exhibit a reduction in HER2, 
estrogen, and progesterone protein expression while increasing proliferation, thus 
adapting a more aggressive TNBC phenotype.   Furthermore, trastuzumab resistant cells 
exhibited a dramatic increase in IL-6/NF-κB positive feedback loop and expanded the 
BCSC population.  Inhibition of IL-6/NF-κB loop by the natural product sulforaphane 
selectively eliminated both BCSCs and inhibits bulk PTEN-deficient trastuzumab-
resistant breast cancer proliferation. These results suggest that following induction of 
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EMT by trastuzumab, and consequent molecular subtype switching, inhibition of the IL-
6/NF-κB positive feedback loop by SF may offer a novel treatment option for 
trastuzumab resistant breast cancers with PTEN deletion.   
Results 
Trastuzumab resistance in breast cancer cells with PTEN deletion induces 
characteristics of the epithelial to mesenchymal transition (EMT)  
In HER2 amplified breast cancer cell line BT474, lentiviral vector containing shPTEN 
was used to knockdown PTEN as reported previously (19). This cell line (BT474 PTEN-) 
was cultured long-term with trastuzumab (LTT, >3 weeks) to induce stable trastuzumab 
resistance (BT474 PTEN- LTT).  In order to establish morphological and phenotypic 
properties of trastuzumab-sensitive and resistant cell lines, we analyzed these cells 
utilizing microscopy and flow cytometry.  Bright field microscopy reveals each 
sequential step in the generation of trastuzumab resistance results in adaption of a more 
mesenchymal like phenotype (Fig. 3.1A).  In addition, there was a dramatic increase in 
expression of basal like markers CD44+ CD24- in trastuzumab resistant BT474 PTEN- 
LTT cells (69.1%) as well as PTEN deleted cells (9.5%) compared to parental BT474 
which lacks this population (Fig. 3.1B).   
To further characterize the parental and trastuzumab resistant cell lines, real time PCR 
analysis of EMT related genes was performed.  While parental BT474 exhibit high 
expression of both E-cadherin and EpCAM, these epithelial markers are at undetectable 
levels in the BT474 PTEN- LTT cell line (Fig. 3.1C).  Conversely, the expression of 
mesenchymal cell markers N-cadherin and vimentin are increased by 16 and 266-fold 
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respectively (Fig. 3.1D).  This data confirms the generation of trastuzumab resistance by 
PTEN knockdown and long term trastuzumab treatment induces characteristics of the 
EMT.  
Induction of EMT associated with trastuzumab-resistance is concurrent with the 
transition to a triple negative like breast cancer.    
In order to explore the potential changes in diverse signaling pathways which may be 
differentially regulated following the induction of EMT by trastuzumab we utilized RNA 
sequencing.  Strikingly, the expression of classical breast cancer subtype markers ER and 
PR were reduced to near undetectable levels while HER2 was reduced 64-fold and Ki-67 
mRNA was increased 4-fold (Fig 3.2A).  These results were confirmed at the protein 
level in each cell line (Fig 3.2B).  When grown in an orthotopic mouse xenograft model 
BT474 cells exhibit strong HER2 staining, intermediate Ki-67, low PR, and no ER as 
determined by immunohistochemistry.  In contrast, BT474 PTEN- LTT xenografts in 
vivo exhibit a higher Ki-67 expression and low to undetectable levels of HER2, PR and 
ER (Fig 3.2C).  ERBB family members are characterized by their homo and hetero 
dimerization upon ligand binding and capable of activation of PI3K and downstream 
AKT signaling nodes.  Consistent with a reduction in HER2 following induction of 
trastuzumab resistance, RNA sequencing revealed a 23% reduction in AKT1 mRNA (Fig 
3.2D).  Similarly, relative quantitation of AKT1 protein expression was reduced 2.25-
fold, as observed by enzyme-linked immunosorbent assay (ELISA), in BT474 PTEN- 
LTT cells when compared to the parental cell line (Fig 3.2E).  
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Induction of trastuzumab-resistance is concurrent with a transition to IL-
6/STAT3/NF-κB signaling. 
The observation that classical breast cancer subtype markers are down regulated suggests 
another signal transduction pathway may play a critical role in proliferation of BT474 
PTEN- LTT cells.  Recent evidence from several groups suggest that triple negative 
breast cancers exhibit a preferential expression of inflammatory cytokines such as IL-6 
and IL-8 (23, 24).  Consistent with previous studies (19), real time PCR demonstrated 
>50-fold up regulation of IL-6 and IL-8 mRNA following the generation of trastuzumab 
resistance (Fig. 3.3A). A quantitative ELISA showed that  IL-6 and IL-8 secreted into 
cell culture media after 72 hr exhibited a 15 and 17-fold enhancement respectively when 
compared to parental cell line (BT474) (Fig. 3.3B).    
Iliopoulos and colleagues propose that IL-6 activation of STAT3, through binding to its 
receptors IL6R and complex formation with GP130, elicits NF-κB mediated IL-6 
production, thus generating a positive feedback loop capable of transforming 
immortalized breast cell line MCF10A (25).   In later work this group and others 
identified that microRNA regulation of PTEN and CYLD is a critical link in this 
“epigenetic switch”, and that IL-6 production in PTEN deficient cells is capable of 
inducing EMT (26).  RNA sequencing results demonstrate that expression of IL-6 co-
receptor GP130, and downstream signaling node STAT3 were increased 22 fold and 54% 
respectively in BT474 PTEN- LTT cells (Fig 3.3C).   Enhanced production of GP130 
mRNA was consistent with the stepwise increase in protein as the parental cell line 
BT474 was subjected to PTEN deletion and long term culture with trastuzumab (Fig. 
3.3D, vimentin increase is displayed as indicator of the EMT).  Further, increased 
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production of IL-6 and GP130 was accompanied by an 86.7% increase in p-STAT3 as 
determined by ELISA (Fig 3.3E).  Since STAT3 has also been shown to activate NF-κB 
to promote IL-6 production (26), a luciferase reporter driven by the NF-κB transcriptional 
response element (TRE) was employed  and demonstrated that BT474 PTEN- LTT cells 
exhibit 17.5 -fold higher NF-κB activity relative to parental BT474 (Fig. 3.3F).  Together 
these results suggest that trastuzumab resistance in PTEN-deficient HER2+ breast cancer 
results in EMT, mediated by IL-6/NF-κB positive feedback loop, to transforms PTEN-
deficient HER2+ breast cancer to a triple negative phenotype (Fig 3.3G). 
Sulforaphane inhibits IL-6/NF-κB signaling loop in breast cancer cell lines.   
Functional activation of canonical NF-κB signaling requires phosphorylation of IκB and 
subsequent nuclear translocation of NF-κB subunits from the cytoplasm followed by 
DNA binding and initiation of transcription (27).  The ability of sulforaphane (SF) to 
inhibit nuclear translocation of p65 as assessed by western blot has been previously 
demonstrated in human prostate cancer cell line PC-3 and breast cancer cell line MCF-7 
(28, 29).  We sought to examine the effect of SF on NF-κB nuclear translocation in 
trastuzumab-resistant breast cancer cells with PTEN deletion. Under typical culture 
conditions p65 resides primarily in the cytoplasm of BT474 PTEN- LTT cells.  Following 
the addition of tumor necrosis factor alpha (TNF-α) in the absence of SF, the NF-κB p65 
subunit translocated to the nucleus, as evident by the disappearance of a clearly defined 
nuclear border (Fig. 3.4A, two left panels). However, stimulation of cells with TNF-α in 
the presence of increasing concentration of SF blocked p65 NF-κB nuclear translocation 
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in a dose dependent manner, with inhibition occurring in some cells at concentrations as 
low as 1 μM (Fig 3.4A, right panels).  
 In order to elucidate whether the inhibition of NF-κB intracellular translocation by SF 
also reduces its transcriptional activity, we employed the NF-κB luciferase reporter assay. 
Following stimulation of BT474 or BT474 PTEN- LLT cell lines with TNF-α, luciferase 
activity increases 4.14 and 2.70-fold (Fig. 3.4B). The enhanced reporter activity is 
substantially reduced by 61% in a dose dependent manner by SF treatment in both BT474 
and BT474 PTEN- LTT. To assess the ability of SF to further regulate endogenous NF-
κB targets, we employed real time PCR and ELISA to monitor the mRNA and protein 
levels of IL-6. We found sulforaphane reduced both mRNA level and secretion of IL-6 
by more than 70% in both BT474 and BT474 PTEN- LTT cell lines (Fig. 3.4C and D).  
Together, these findings provide evidence that sulforaphane (SF) is able to disrupt IL-
6/NF-κB signaling across breast cancer cell lines.   
Sulforaphane selectively inhibits trastuzumab-resistant breast cancer cells with 
PTEN deletion in vitro.   
The significant up-regulation of IL-6/STAT3/NF-κB in BT474 PTEN- LTT cells relative 
to parental BT474, along with the inhibition of this pathway by SF, suggests that it may 
exhibit preferential efficacy in the trastuzumab resistant cell line.  Thus, we utilized the 
MTS proliferation assay to compare sensitivity of BT474, BT474 PTEN-, and BT474 
PTEN- LTT cells to SF (Fig. 3.5A). SF exhibited a poor reduction in proliferation of 
BT474 at concentrations as high as 50 μM over 72 hours.  Strikingly, deletion of PTEN 
resulted in a sensitization of the cell line to SF with 50% reduction in proliferation 
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established at 29.06 μM. BT474 PTEN- LTT cells further displayed a marked increase in 
their sensitivity to SF with IC50 reduced to 8.96 μM, demonstrating a strong link 
between IL-6/STAT3/NF-κB signaling and SF sensitivity in trastuzumab-resistant breast 
cancer cells with PTEN deletion.   
Previous reports from our laboratory have identified the efficacy of SF in basal/claudin-
low SUM159 which exhibited an IC50 of approximately 10 μM (30), and is significantly 
different when compared to that of HER2 amplified BT474.  To identify if the presence 
of HER2 is responsible for reduced efficacy of SF, we overexpressed this receptor in 
SUM159. Indeed, overexpression of HER2 in SUM159 cells resulted in a near doubling 
of IC50 from 7.63 to 13.22 μM (Fig. 3.5B).   Furthermore, shRNA knockdown of PTEN 
in SUM159 HER2+ cells, restored sensitivity of these cells to sulforaphane. Taken 
together, these results suggest that SF preferentially suppresses proliferation in cell lines 
which primarily rely on IL-6/NF-κB for their survival, whereas strong activation of 
HER2/AKT signaling may predict resistance to SF (Fig. 3.5C).    
Sulforaphane preferentially reduces breast cancer stem cells (CSC) and bulk tumor 
volume in trastuzumab-resistant xenograft models.   
To assess the ability of sulforaphane (SF) to inhibit tumor growth compared to 
conventional therapy (docetaxel and trastuzumab) we implanted BT474 PTEN- LTT and 
BT474 cells into NOD/SCID mice and began treatment after the tumor volume reached 
40 mm
3
.  Docetaxel and trastuzumab were administered via IP injection once weekly 
while sulforaphane (SF) was administered daily.  In BT474 PTEN- LTT xenograft 
bearing mice, 10 doses of SF significantly reduced tumor volume by 51.8% (Fig. 3.6A).  
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Daily SF treatment ultimately resulted in a 61.0% reduction in tumor volume relative to 
saline control, an effect that is comparable to that of docetaxel (60.1%) which serves as a 
positive control for bulk tumor volume reduction.  As expected, treatment of mice with 
weekly IP injections of trastuzumab resulted in no statistically significant change in 
tumor volume. Conversely, in BT474 xenografts SF was only able to produce a 
significant reduction in tumor volume (47.4%) after 30 doses (Fig 3.6B).  Histological 
staining of primary xenografts using haematoxylin and eosin reveal significantly larger 
areas of necrosis with BT474 PTEN- LTT cells treated with SF in comparison with SF 
treated BT474 or control xenografts (Fig 3.6C). 
We further confirmed that SF preferentially reduced CSCs (Fig. 3.6D and E) in BT474 
PTEN- LTT versus parental BT474 tumors using secondary reimplantation assay with 
extreme limiting dilution analysis (ELDA)(31). When control tumor volumes reached 
protocol specific endpoint xenografts were dissociated into a single cell suspension 
FACS sorted for the use in secondary reimplantation assays.  Nine weeks post-
reimplantation of vehicle treated tumors from mice bearing BT474 PTEN- LTT 
xenografts demonstrated a tumor initiating frequency of 1/522 cells (Fig. 3.6D). In 
contrast, residual tumors from sulforaphane (SF) treated mice showed significantly lower 
tumor initiating frequency (1/2807 cells) when implanted into secondary mouse fat pads. 
BT474 PTEN- LTT xenografts treated with trastuzumab had a significant increase in 
frequency of tumor initiating cells (1/112 cells p=0.015 vs. 1/522 cells in control group).  
The tumors from docetaxel treated mice showed a modest increase of tumor initiating 
frequency relative to control, consistent with previous reports (32).   Secondary 
implantation from BT474 xenografts treated with SF demonstrated only a modest 
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decrease in tumor initiating cell frequency, with 1/1245 cells in SF treated group  
vs.1/558 cells in control group p=0.247 (Fig. 3.6E).   
In order to simulate if SF treatment would be beneficial as adjuvant therapy in patients 
following surgical resection of tumors, and inhibit breast CSC tumor initiation, we 
utilized an early treatment xenograft model.  Two days following inoculation of BT474 
PTEN- LTT cells, animals were randomized and treated with 10 mg/kg SF, 50 mg/kg SF, 
or saline vehicle.  Daily dosing was continued until control tumors reached a volume of 
100 mm
3
 at which point treatment was stopped and tumor monitoring was continued.  
Over the course of treatment 50 mg/kg SF prevented 66.7% of tumors from forming in 
mice implanted with BT474 PTEN- LTT, an effect persistent 30 days after 
discontinuation of treatment (Fig. 3.6F). Furthermore, administration of 10 mg/kg 
reduced tumor formation 31.25%, revealing a dose dependent therapeutic effect.  In 
addition, SF treatment inhibited BT474 PTEN-LTT tumor volume by 68.7% and 87.3% 
at doses 10 and 50 mg/kg respectively (Fig. 3.6G). 
Discussion  
The contribution of the tumor suppressor PTEN to efficacy of trastuzumab in HER2 
amplified breast cancer patients has been previously reported in the literature.  
Inactivation of PTEN is associated with reduced function of trastuzumab in BT474 and 
SKBR3 cell lines in vitro and correlates with poor response to trastuzumab in patients 
(10, 33).  However the translation of these findings to clinical application of trastuzumab 
to patients has yet to be fully realized, where HER2 amplified patients regardless of 
PTEN status are usually treated with trastuzumab in combination with surgery, 
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radiotherapy, and conventional chemotherapies depending upon expression of other 
hormone receptors, tumor size, lymph node status, and the presence of distant metastasis. 
Since it is unknown what the potential clinical consequences of continued use of 
trastuzumab as a therapy in HER+ PTEN deficient patients we sought to explore this 
using genetic manipulation and drug conditioning in the breast cancer cell line BT474.   
Consistent with a previous report we demonstrate that long term culture with trastuzumab 
in BT474 containing reduced PTEN function (shPTEN) induces morphological and 
transcriptional changes characteristic of the epithelial to mesenchymal transition in a 
stepwise manner (19).  These results suggest deletion of PTEN may be critical for 
priming the cells for further transformation.  Iliopoulos et. al. have demonstrated that 
microRNA targeting of PTEN is a critical step in triggering transformation of the 
immortalized MCF-10A cell line by IL-6 (25, 26).  More recently, transformation of 
MCF-10A by PTEN and p53 knockdown has been shown to generate a triple negative 
type breast cancer cell line (24).   
Upon further characterization of BT474 PTEN- LTT cells, we identified that expression 
of classical breast cancer cell markers ER, PR, and HER2 were all significantly reduced 
at mRNA and protein level both in vitro and in vivo, while expression of proliferation 
marker Ki-67 was increased.  This stably resistant cell also exhibited a reduced mRNA 
and protein level of downstream signaling node AKT1 which can be regulated by 
multiple ERBB family members.  This is consistent with previous reports demonstrating 
that culture with trastuzumab significantly down regulates HER2 protein in the HER2+ 
MDA-MB-453, which contains mutations in both PIK3CA and PTEN (34-36).  Multiple 
studies have utilized BT474 in xenograft model, treated with trastuzumab, which provide 
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insight into the molecular mechanisms associated with acquired trastuzumab resistance 
(37, 38).  In vivo, these studies report trastuzumab treatment does not cause a significant 
down regulation of HER2 and resistant cell lines remain dependent on ERBB family 
signaling. However, our data showed that continued use of trastuzumab in HER2+ breast 
cancer with PTEN inactivation induces EMT and in the conversion to a triple negative 
molecular subtype. Taken together with our results these studies may suggest that the 
generation of acquired and de novo trastuzumab resistance exhibit two distinct molecular 
mechanisms, with patients exhibiting PTEN deletion at high risk for the observed 
molecular subtype switching.    
Following the generation of trastuzumab resistance in HER2+ breast cancer cells with 
PTEN deletion, the mRNA and protein level of inflammatory cytokines IL-6 and IL-8 
were dramatically unregulated.  Indeed we postulate that IL-6 is the main driver of the 
EMT induction process.  Constitutive expression of IL-6 in MCF-7 results in a dramatic 
reduction in E-cadherin while up regulating mesenchymal markers N-cadherin, vimentin, 
and twist (39).  Similarly, IL-6 stimulation of CD44-CD24+ breast cancer patient derived 
cells has been demonstrated to reduce E-cadherin expression and generate a 
CD44+CD24- population.  Further, the induction of EMT in Ras-transformed mammary 
epithelial cells has also been shown to rely on NF-κB signaling (40), which has 
previously been shown to be activated through the IL-6/STAT3/NF-κB positive feedback 
loop (13, 17, 25).   Consistent with these reports we find that with the reduction of 
HER2/AKT signaling there is a significant increase in IL-6, GP130, level of p-STAT3, 
and activity of the NF-κB transcription factor.   
 88 
 
In previous reports sulforaphane (SF) has been demonstrated to inhibit NF-κB 
transcriptional activity by preventing p65 DNA binding activity in pancreatic and breast 
cancer cell lines (41, 42).  Additionally, in prostate cancer cell lines SF reduced NF-κB 
nuclear translocation and transcriptional activity (43). Further, SF’s activity in pancreatic 
CSCs has been attributed to inhibition of the NF-κB transcription factor (41, 44).   In this 
report, we demonstrate that SF is capable of disrupting NF-κB p65 translocation, 
transcriptional activity, and inhibiting endogenous target IL-6 at mRNA and secreted 
protein level across breast cancer cell lines.   While SF did not inhibit proliferation of 
parental BT474 it inhibited the growth of BT474 with PTEN deletion and long term 
culture with trastuzumab both in vitro and in mouse xenograft model.  Additionally, the 
inhibitory effect of SF on both tumor volume and tumor initiation in secondary mice was 
preferentially observed in trastuzumab-resistant BT474 PTEN- LTT relative to BT474 
xenografts.  Of note, the reduction of bulk tumor volume by SF in trastuzumab-resistant 
xenografts, at the indicated dosing regimen, was comparable to that of conventional 
chemotherapy while the additional ability to reduce tumor initiating cell frequency was 
observed.   
These data suggest that continued use of trasuzumab in drug-resistant HER2+ breast 
cancer with PTEN deletion may pose potential challenges for therapeutics of HER2+ 
breast cancers via induction of EMT, expansion of BCSC populations, and by switching 
the molecular subtype to triple negative. Further, adjuvant SF treatment may provide a 
novel strategy towards targeting both bulk tumor volume and breast cancer stem cells in 
trastuzumab-resistant breast cancers with PTEN deletion in patients by disrupting the IL-
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6/NF-κB.  Further clinical investigation may be warranted to explore the role of this 
phenomenon in breast cancer patients with different status of PTEN and HER2. 
Materials and Methods 
Cell Culture and Reagents. Cell lines and culture conditions can be obtained in SI 
Material and Methods.  Sulforaphane was obtained from Quality Phytochemicals LLC 
(New Jersey, USA) and diluted in DMSO (< 0.1%) for in vitro studies or 0.9% saline in 
vivo.  Docetaxel (Hospira) and Trastuzumab (Herceptin, Genentech) were obtained 
through the University of Michigan Cancer Center Pharmacy.     
Quantification of mRNA.  Total RNA from cell lines was extracted using RNeasy mini 
kit (Qiagen) according to manufacturer’s protocol.   Purified total RNA was further 
prepared for RNA-sequencing using TruSeq RNA sample preparation kit (Illumina) 
followed by 50 cycle, single end reads carried out using the HiSeq 2000 sequencing 
system (Illumina).  RNA expression analysis was performed by normalization using reads 
per kilobase per million reads (RPKM) method.   RNA purified for real time PCR 
analysis was converted to cDNA using the M-MLV RT (Promega) and subjected to real 
time PCR analysis using TaqMan universal PCR master mix (Roche) and indicated 
primers using ABI PRISM 7900GT sequencing detection system (Applied Biosystems).  
Luciferase Reporter Assay.  Lentiviral particles containing luciferase reporter construct 
driven by NF-κB (System Biosciences) were obtained and transfected into BT474 and 
BT474 PTEN- LTT cells.  Two hours following incubation with SF, TNF-α 
concentration in media was brought to 50 ng/ml. After 6 hr Luciferase activity was 
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measured according to manufacturer’s instructions with oneGlo reagent (promega) on 
Synergy 2 plate reader (BioTek). 
Protein Expression Analysis.  After culture for 72 hours media or cells were collected 
and subjected to ELISA for Human IL-6, IL-8, AKT, and p-STAT3.  Assays were 
performed using antibody kits for AKT and p-STAT3 (Cell Signaling Technology) or IL-
6 and IL-8 (Duosets, R&D Systems) according to manufacturer’s protocol.  Data was 
acquired with a BioTek Synergy plate reader and analyzed using Gen5 software.  
Antibodies for western blot (HER2, PR α/β, ER α, PTEN, GP130, Vimentin, β-actin, and 
secondary antibodies) were obtained from Cell Signaling Technology. 
Flow Cytometry and Immunostaining.  Flow cytometry analysis of cell lines in vitro 
was performed using anti-CD44-APC, anti-CD24-FITC, and corresponding isotype 
antibodies (BD Biosciences) on a SY3200 (Sony Biotechnology) flow cytometer.  
Immunofluorescent staining of p65 NF-κB (Cell Signaling Technology) in BT474 PTEN- 
LTT cell line was performed in 4-well glass chambers slides (lab-tek) following 
pretreatment with SF for 2 hours and 30 min and 50 ng/ml TNF-α for 2 hours.  Cells were 
fixed and permeabilized with methanol/acetone followed by blocking with 3% BSA.  
Nuclear staining was identified with 1 µg/ml DAPI and imaging was carried out with a 
Nikon Eclipse TE2000-S microscope and MetaMorph 7.6.0.0 (Molecular Devices). 
MTS Cell Proliferation Assay.  Cell lines were plated at a density of 3,000 cells per 
well in 96-well plates and allowed to adhere overnight.  Following 72 hour incubation 
with SF proliferation was determined by MTS assay according to manufacturer’s 
instruction.  Absorbance at 490 nm was measured using Synergy 2 plate reader.  
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Pharmacodynamic modeling was performed using a nonlinear, variable slope model in 
GraphPad Prism (GraphPad Software).   
Mouse Xenograft Models.  Female 5 week old non-obese diabetic/severe combined 
immunodeficient (NOD/SCID) mice were obtained from Jackson Laboratory. Xenograft 
formation in advanced treatment model was generated by direct injection of BT474 or 
BT474 PTEN- LTT cells (1,000,000), suspended in matrigel (BD Biosciences), into the 
exposed no.4 inguinal mammary pad.  Trastuzumab (10 mg/kg once every 7 days), 
sulforaphane (50 mg/kg daily), and docetaxel (10 mg/kg once every 7 days) were 
administered via I.P. injection beginning when tumor volume reached approximately 40 
mm
3
 or the day after surgery for adjuvant treatment model.  When control tumors reached 
approximately 500 mm
3
 mice were euthanized with CO2 inhalation and tumors resected. 
Secondary Reimplantation Assay.  Isolated primary tumors were mechanically and 
enzymatically dissociated using gentleMACS Octo Dissociator and tumor dissociation kit 
(Miltenyi Biotec) according to manufacturer’s instructions.  Human tumor cells with 
DsRed label were then isolated using fluorescent activated cell sorting on a SY3200 
(Sony Biotechnology) flow cytometer. Secondary mice were inoculated with 10,000, 
5,000, or 1,000 cells for BT474 xenografts and 5,000, 1,000, or 200 cells for BT474 
PTEN- LTT xenografts as described above.  Tumor formation rate in secondary mice was 
assessed 9 weeks following implanting cells by direct palpitation.  
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Figure 3.1 Trastuzumab-resistant BT474 with PTEN deletion exhibits mesenchymal 
phenotype and increases cancer stem cells. (A) Representative bright field microscopy 
images of BT474, BT474 shPTEN, and BT474 shPTEN with long term treatment of 
trastuzumab (LTT). Original images obtained with 20X objective. (B) Left, percent of 
cells expressing basal breast cancer markers CD44+/CD24- in cell lines as assessed by 
flow cytometry. N=3. Right, representative CD44 and CD24 flow cytometry analysis of 
each. (C)  Real time PCR quantification of epithelial cell makers E-cadherin and EpCAM 
normalized to expression of GAPDH.  (D)  Real time PCR analysis of mesenchymal cell 
markers N-cadherin and Vimentin, expressed relative to GAPDH.  N=4, Data shown as 
average ± SD.  # p ≤ 0.01. 
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Figure 3.2 Induction of EMT associated with trastuzumab-resistance is concurrent 
with the transition to a triple negative like breast cancer.  (A) Normalized mRNA 
expression (reads/kilobase/million reads) of breast cancer subtype markers ER, PR, 
HER2, and Ki-67 determined by RNA sequencing in Parental BT474 and BT474 PTEN- 
LTT cell lines N=4.(B) Western blot representing breast cancer subtype markers ER, PR, 
HER2 and PTEN with β-actin as loading control. (C)  Immunohistological staining of 
breast cancer subtype markers in primary BT474 and BT474 PTEN- LTT xenografts 
when tumors reached 500 mm
3
.  (D) mRNA expression of HER2 signal transducer AKT1 
as determined by RNA sequencing.  (E) Normalized protein expression of AKT1 in cell 
lines by ELISA assay. N=3. Data shown as average ± SD.  # p ≤ 0.01. 
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Figure 3.3  Induction of trastuzumab-resistance is concurrent with a transition to 
IL-6/STAT3/NF-κB signaling. (A)  mRNA expression of endogenous inflammatory 
cytokines IL-6 and IL-8 normalized to GAPDH as identified by real time PCR. N=4 (B) 
Protein expression in pg/ml of IL-6 and IL-8 secreted into culture media, measured using 
quantitative enzyme-linked immunosorbent assay (ELISA). N=3 (C) Normalized mRNA 
expression (reads/kilobase/million reads) of IL-6 signal transducer GP130 (left) and 
downstream signaling node STAT3 (right) by RNA-sequencing. N=4 (D) Western blot 
analysis of protein expression for GP130, mesenchymal cell marker vimentin, and PTEN 
tumor suppressor in BT474, BT474 PTEN-, and BT474 PTEN- LTT cell lines. (E)  
ELISA relative quantitation of active STAT3, phosphorylated at Tyr705. N=3 (F) 
Luciferase activity of cell lines following infection of with retroviral vector inducing NF-
κB driven expression of luciferase. N=3. (G) Model of trastuzumab resistance in PTEN 
deficient cells, T.F.s = other transcription factors. Data shown as average ± SD. * p ≤ 
0.05.  # p ≤ 0.01.  
 98 
 
 
Figure 3.4 Sulforaphane inhibits IL-6/NF-κB signaling loop in breast cancer cell 
lines.  (A)  Immunofluorescent staining of NF-κB p65 subunit and DAPI in fixed BT474 
PTEN- LTT cells exhibits primarily cytoplasmic staining (left).  Translocation of p65 
from cytoplasm to nucleus, induced using 50 ng/ml TNF-α, is prevented by pretreatment 
with SF in a dose dependent manner (right three panels). Red arrows indicate boarder 
between cytoplasm and nucleus of a representative cell.  Original images were obtained 
using a 20X microscope objective. (B) BT474 PTEN- LTT and BT474 cell lines were 
transfected with NF-κB luciferase reporter.  Luciferase reporter activity was obtained in 
the absence or presence of 50 ng/ml TNF-α in combination with increasing 
concentrations of SF. (C) mRNA expression of endogenous inflammatory cytokine IL-6 
normalized to GAPDH as identified by real time PCR in the presence of increasing 
concentration of SF.  (D)  Quantitative ELISA identifying protein level endogenous NF-
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κB target protein IL-6 when cell lines are incubated with increasing concentrations of SF 
for 72 hr.  (B-D) N=3.  Data are shown as averages ± SD. *p ≤ 0.05. # p ≤ 0.01. 
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Figure 3.5 Sulforaphane (SF) selectively inhibits trastuzumab-resistant breast 
cancer cells with PTEN deletion in vitro.  MTS proliferation assay (Promega) was 
carried out after incubating cell lines with increasing concentration of SF for 72 hours. 
(A) PTEN knock down and long term trastuzumab (LTT) culture with HER2 amplified 
BT474 sensitizes the cell line to SF.  (B) MTS assay performed in triple negative 
SUM159, SUM 159 with shPTEN, SUM159 with HER2 over expression, and SUM159 
shPTEN with HER2 overexpression.  (C)  Model of SF efficacy demonstrating cell lines 
with HER2 amplification in the absence of PTEN deletion are likely to be insensitive to 
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SF treatment whereas deletion of PTEN is likely to enhance efficacy. (A and B) N= 6. 
Data are shown as averages ± SD.  
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Figure 3.6  Sulforaphane (SF) reduces the breast cancer stem cells (CSC) population 
and bulk tumor volume in trastuzumab-resistant advanced xenograft model.  (A) 
NOD/SCID mice bearing 40 mm
3 
BT474 PTEN- LTT xengrafts were randomized into 
treatment groups, 50 mg/kg SF and 10 mg/kg Doc were sufficient to significantly reduce 
bulk tumor volume within 10 days. Trastuzumab treatment produced no significant 
reduction in tumor volume for BT474 PTEN- LTT xenografts over the course of the 
experiment. * p ≤ 0.05. (B) Tumor volume of mice bearing primary BT474 xenografts, 
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30 doses of SF were required to significantly reduce tumor volume. Arrow denotes the 
beginning of treatment in primary mice. * p ≤ 0.05.   (A and B)  Tumor volume 
represented SD of N=6 mice.  (C) Representative H&E staining of primary BT47 and 
BT474 PTEN- LTT tumors. SF treatment in BT474 PTEN- LTT xenografts generated 
intratumoral regions of necrosis (red arrows) whereas this was not observed in BT474 
xenografts. Primary xenografts were removed, dissociated, and serially reimplanted into 
secondary mice to determine the tumor initiating CSC frequency by extreme limiting 
dilution analysis of primary (D) BT474 PTEN- LTT and (E) BT474 xenografts. (F) 
Tumor formation rate of mice injected with 50,000 BT474 PTEN- LTT cells followed 2 
days later by daily SF treatment. Control N=16, 10 mg/kg N=16, 50 mg/kg N=12. (F) 
Average volume of BT474 PTEN- LTT xenografts that formed with adjuvant treatment. 
Control N=16, 10 mg/kg N=9, 50 mg/kg N=4.  
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Chapter 4 
MEOX1 as a Novel Cancer Stem Cell Target for Treatment of Trastuzumab-
Resistant HER2
+ 
Breast Cancers 
Abstract 
The development of resistance to trastuzumab in HER2+ breast cancer patients represents 
a significant clinical challenge.  Accumulating evidence suggests that inactivation of the 
tumor suppressor PTEN may predispose HER2+ patients to the development of 
resistance to trastuzumab therapy.  Knockdown of PTEN and long term culture with 
trastuzumab (LTT) has been demonstrated to induce the epithelial to mesenchymal 
transition (EMT) and expand the breast cancer stem cell (CSC) population.  In this study 
we apply RNA sequencing to identify novel targets which can be exploited for the 
development of therapeutics for PTEN deficient patients following the generation of 
trastuzumab resistance.  Gene expression analysis reveals 3901 differentially expressed 
genes between trastuzumab sensitive BT474 and trastuzumab resistant BT474 shPTEN 
LTT cell lines. Using the natural product sulforaphane which exhibits preferential 
efficacy in BT474 shPTEN LTT cells, in conjunction with differentially expressed genes 
following trastuzumab resistance, we identify a set of 44 candidate genes for the 
treatment of trastuzumab resistant patients. Of these genes siRNA to MEOX1 reveal it to 
be a critical factor for bulk cell line proliferation and regulation of breast cancer stem 
cells.  In addition, MEOX1 expression was enriched in TNBC patient tissues and 
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inversely correlated with PTEN expression.  These studies demonstrate MEOX1 is a 
novel target for drug development which may provide clinical benefit to breast cancer 
patient with poor clinical prognosis. 
Introduction  
Accumulating evidence has shown that many tumors, including breast cancer, are 
initiated from and maintained by a small population of cancer stem cells (CSCs)(1). 
Current cancer treatment strategies may reduce tumor bulk but in some cases fail to 
eradicate cancer stem cells (CSCs), leading to chemotherapy and radiotherapy 
resistance(2). Therefore, targeting CSCs provides a novel therapeutic strategy for cancer 
treatment to improve cancer patients outcome. 
HER2
+
 breast cancers typically respond well to trastuzumab treatment, particularly in 
early stage diseases. However, in metastatic HER2+ breast cancers the majority of 
patients will either demonstrate de novo trastuzumab resistance or acquired trastuzumab 
resistance after one to two year of treatment(3-5). Previous studies have shown that 
approximately 40% of HER2
+
 breast cancers have reduced expression of the PTEN tumor 
suppressor (6, 7). Reduced PTEN activity mediates trastuzumab resistance via activation 
of the downstream signaling molecule AKT, bypassing the requirement for HER2 
activation.  Additionally, inactivation of PTEN in HER2 overexpressing cell lines results 
in activation of cross-talk between AKT and NF-kB signaling nodes(8). We and others 
have demonstrated trastuzumab treatment in HER2+ PTEN inactivated cell lines 
generates the epithelial to mesenchymal transition (EMT), expands breast CSCs, and 
establishes a positive feedback loop between IL-6/STAT3/NF-kB (9). The resistance 
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generated in these PTEN deficient cancers is stable even without trastuzumab treatment 
for greater than 1 month, and is thought to be maintained by the IL-6/NF-kB positive 
feedback.  However, the induction of EMT and expansion of breast CSCs may activate 
diverse signaling pathways which are functionally relevant with respect to proliferation 
and self –renewal but have yet to be exploited as drug targets in trastuzumab resistant 
breast cancers(10, 11).   
Sulforaphane (SF), a natural compound derived from broccoli sprouts, has shown to be 
effective at abrogating CSCs in breast, pancreatic, and prostate cancers. Previously, we 
have shown that SF was able to decrease the ALDH+ cell population in TNBC cell lines 
and suppress secondary tumor formation in vivo (12). Similarly in prostate and pancreatic 
cancer cell lines SF reduces CSC function in vitro and in vivo as evident by reduced 
tumorsphere formation, colony formation, and secondary tumor formation in mice(13-
15). In addition, our reports and those of others demonstrate the efficacy of SF as both a 
single agent therapeutic and in combination with other therapies to effectively eliminate 
both bulk cells and CSCs (15, 16).  However, due to the staggering number of proposed 
mechanisms of action attributed to SF’s efficacy, including those by our laboratory, it 
remains a possibility that SF may have a context dependent inhibition on certain 
signaling pathways. Regardless of proposed mechanisms, the efficacy of SF in breast 
CSCs and specific subtypes of breast cancer make it a valuable small molecule probe 
which can be utilized to interrogate pathways that may be critical to inhibition of CSCs 
across cancer types.  However in order to determine which of the many pathways SF may 
regulate, and which is responsible for its selective efficacy in trastuzumab resistant breast 
cancers, a more global approach to gene expression analysis is needed. 
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HOX genes, encoding homeodomain-containing master regulators of embryonic 
development, play key roles in stem cell proliferation and differentiation(17). Further, 
reports have shown that HOX genes can be re-expressed in cancerous cells following 
transformation and have been associated with cancer progression(18). MEOX1, a 
homeobox transcription factor, is well-established as one of the key transcriptional 
regulators during embryonic development by interacting with multiple signaling 
pathways (19, 20). In cancer, MEOX1 has been shown to participate in PBX1 
transcriptional activity, potentially mediating PBX1-related growth signaling (21).  
However, the potential role of MEOX1 in regulating self-renewal of CSCs and 
proliferation of bulk tumor cells in trastuzumab resistant cell lines has yet to be explored.  
In this report, we study the differences in global gene expression profiles between 
trastuzumab sensitive BT474 and resistant BT474 shPTEN with long term trastuzumab 
culture (>3 weeks, BT474 PTEN- LTT) by RNA sequencing (RNA-seq). Conversion of 
the BT474 cell lines to trastuzumab resistant BT474 PTEN- LTT resulted in a cell line 
which was capable of enhanced mammosphere formation and metastasis.  Further, this 
conversion was associated with increased expression of EMT-like breast CSC markers 
and reduced expression of MET-like breast CSC markers. Using the natural product SF, 
which preferentially inhibits trastuzumab resistant BT474 PTEN- LTT cells and the 
breast CSCs within them, we identify novel gene targets capable of the same. 
Characterization of genes upregulated in BT474 PTEN- LTT cells and downregulated by 
SF in dose dependent manner identified MEOX1 as a novel potential drug target for the 
treatment of trastuzumab resistant PTEN- breast cancers. Using siRNA knockdown, we 
confirm that MEOX1 is functionally capable of regulating bulk cell proliferation, 
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mammosphere formation, and colony formation in soft agar.  Interestingly, in an 
additional cell line MDA-MB-453 MEOX1 expression was significantly correlated with 
that of ALDH1A1.  Immunohistochemical (IHC) staining of a breast cancer tissue 
microarray (TMA) revealed MEOX1 is expressed at high levels in TNBCs from patients 
and is significantly correlated with PTEN deletion. Our findings suggest that MEOX1 is a 
novel regulator of both breast CSCs and proliferation of bulk tumor cells in trastuzumab 
resistant breast cancers and potentially a subset of TNBCs.   
Results 
Trastuzumab resistance dramatically alters signal transduction in PTEN- breast 
cancer cells 
In order to reveal the potential genes involved in trastuzumab resistance and the EMT 
phenotype observed in BT474 PTEN- LTT cells an RNA-seq approach was used to 
compare all mRNA transcripts in BT474 and BT474 PTEN- LTT cell lines. Data analysis 
was performed based on the random variance model (RVM) algorithm (p-value < 0.05, 
FDR < 0.05) and genes which exhibit great than 2-fold change as evident by RNA-seq.  
This revealed 3901 genes which were differentially regulated between the two cell lines, 
including 2023 up-regulated genes and 1878 down-regulated genes following the 
generation of trastuzumab resistance (Fig. 4.1A, left). Gene ontology (GO) enrichment 
analysis was then employed to categorize the attributes associated with differentially 
regulated genes. GO analysis revealed that BT474 PTEN- LTT cells overexpress genes 
that are significantly associated with 3 functions; focal adhesion, extracellular matrix and 
receptor interactions, and pathway in cancer progression.  While largely general in scope, 
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pathways in cancer progression includes Cytokine/NF-kB, HIF-1α, and WNT signaling 
pathways among others.  Conversely, down-regulated genes were enriched for pathways 
which primarily promote metabolic activity (Fig. 4.1A, right).  
Previously, we have identified that trastuzumab resistance induces EMT and that BT474 
PTEN- LTT cells adapt a TNBC phenotype.  In order to validate these results gene set 
enrichment analysis (GSEA) was performed on the differentially regulated gene set 
between BT474 and BT474 PTEN- LTT cells and enrichment scores (ES) and their 
associated p-values obtained (Fig. 4.1B).  GSEA reveals that the trastuzumab resistant 
BT474 derivative exhibits similar gene expression to cells which have transitioned to a 
mesenchymal cell type (ES=0.81, p-value<0.01).  Similarly, the genes which were down 
regulated after the generation of trastuzumab resistance were enriched in a data set 
encompassing genes which are lower in basal breast cancer cell lines when compared to 
luminal (ES=0.76, p-value<0.01).  Together, these results independently confirm our 
previous observation that the generation of trastuzumab resistance in PTEN- BT474 cells 
results in EMT and the conversion to a TNBC subtype.   
In order to validate the reports of Korkaya et.al that expansion of breast CSCs follows the 
generation of trastuzumab resistance, mammosphere formation assay was performed and 
resulted in BT474 PTEN- LTT cells exhibiting 2.4-fold higher sphere formation potential 
(Fig. 4.1C) (9).  In further in vivo studies, these cells were capable of producing macro-
metastasis in lymph nodes whereas parental BT474 xenografts are not (Fig. 4.1D). It is 
expected that an increase in the CSC population could be observed by alterations in gene 
expression of common breast CSC markers at the mRNA level.  While the expression of 
CD44 was increased 20.4-fold and CD24 was reduced 6.7-fold as expected, expression of 
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ALDH1A1 and ALDH1A3 were dramatically reduced 682-fold and 9.6-fold respectively 
(Fig 4.1E). These ALDH enzymes are thought to be the isoforms largely responsible for 
activity of the Aldefluor assay.  This data suggests that not only have BT474 PTEN- LTT 
cells adapted a TNBC phenotype, but the CSCs within them have transitioned from an 
MET like state to an EMT like state.     
Generation of trastuzumab resistance in BT474 with PTEN deletion is unlikely to 
occur through traditional mechanisms 
Due to the importance of trastuzumab resistance numerous studies have identified 
potential drug resistance mechanism in HER2+ breast cancer (22-25).  First, the epitope 
to which trastuzumab binds may be removed by shedding of the extracellular HER2 
domain or masked by additional proteins thereby preventing access to the binding site.  
Further, activation of other ERBB family members and their corresponding ligands 
provide an additional mechanism by which downstream PI3K and AKT can be activated 
even in the presence of HER2 inhibition.  Likewise, activation of additional signaling 
molecules by HER2, such as IGF-1R can lead to a diverse variety of additional 
downstream signaling nodes.  In order to evaluate if these changes are likely responsible 
for our observed phenotype change we sought to look at the expression of proteins 
responsible for the proposed mechanisms above via RNA-seq.  In addition to the 
observed reduction in HER2 noted earlier, expression of ERBB receptor family members 
HER3 and HER4 were reduced 80 and 25-fold respectively (Fig 4.2A).  While EGFR 
was significantly upregulated 6.4-fold the expression of its ligand EGF was reduced 12.8-
fold, as well as, the major ligands associated with the HER3 and HER4 (BTC and HRG).  
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Further, MUC4 which has previously been associated with antigen masking was reduced 
6.6-fold in the BT474 PTEN- LTT cells and IGF-1R exhibited only a modest increase of 
27.6% in expression (Fig 4.2B).  Due to the down regulation of most ERBB family 
receptors, their ligands, MUC4, and only modest changes in IGF-1R, taken together with 
the importance of additional pathways, it is reasonable to assume that classical 
trastuzumab resistance mechanisms are unlikely to account for the resistance observed in 
PTEN deficient BT474.   
Sulforaphane preferentially regulates MEOX1 mRNA in trastuzumab resistant 
breast cancers. 
The dramatic alterations in signal transduction following PTEN knockdown and LTT 
make identifying novel regulators of trastuzumab resistance difficult.  However, SF 
elicits a therapeutic response only in trastuzumab resistant cells in vitro (Fig 4.3A).  By 
coupling the treatment of SF with analysis of differentially expressed genes in BT474 and 
BT474 PTEN- LTT cells it may be possible to narrow down which targets are responsible 
for regulating proliferation and CSCs within these cell lines.  To this end both parental 
and BT474 PTEN- LTT cells were treated with increasing concentrations of SF (2 and 10 
μM) to identify dose dependent changes in gene expression.  In addition, both cell lines 
were treated with a dose of SF capable of inhibiting bulk cell line proliferation 
specifically within the BT474 PTEN- LTT cells at 8 and 24 hours to identify time 
dependent gene expression changes.  
With increasing SF concentration and duration of treatment in both cell lines RNA-seq of 
total isolated mRNA was performed (Fig 4.3B). A Venn diagram illustrating the number 
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of genes down regulated >2-fold in the trastuzumab resistant cell line under different 
treatment conditions reveals that only 110 gene candidates exhibit both time and dose 
dependent inhibition by SF (Fig 4.3C).  Of these 110 genes only 44 are upregulated >2-
fold in BT474 PTEN- LTT cells relative to the parental cell line (Fig 4.3D).  Functional 
GSEA reveals that only one functional group is enriched within these 44 genes, 
Homeobox transcription factors (Fig 4.3E). Among these genes MEOX1 displays the 
highest mRNA expression in BT474 PTEN- LTT cells and its expression was nearly 
undetectable in BT474 cells (2989-fold upregulated). Thus it was identified as the top 
candidate gene for further analysis.   
Sulforaphane reduces MEOX1 protein expression in vitro and in vivo. 
In order to evaluate if the reduction of MEOX1 mRNA led to a reduction in protein 
expression immunofluorescent staining of MEOX1 was performed. Under typical culture 
conditions for BT474 PTEN- LTT cells in vitro MEOX1 resides primarily within the 
nucleus, as evident by overlap between MEOX1 (Green) and DAPI (Blue) staining (Fig 
4.4A).  The addition of 10 μM SF for 24 hours led to a reduction in both overall intensity 
and number of MEOX1 nuclear foci, suggesting SF reduces MEOX1 protein expression 
in vitro.  In order to validate if SF was capable of reducing MEOX1 expression in vivo 
and advanced treatment orthotopic mouse xenograft model was employed using the 
BT474 PTEN- LTT cell line.  Daily treatment of mice with 50 mg/kg SF significantly 
reduced the tumor mass when primary treatment ended (Fig 4.4B, left), and as previously 
identified SF reduced the frequency of CSCs within these tumors based on secondary 
reimplantation with extreme limiting dilution analysis (ELDA)(Fig 4.4B, right). A 
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section of primary tumor was harvested before ELDA and immunohistochemical (IHC) 
staining of MEOX1 was performed (Fig 4.4C). IHC demonstrates that the use of SF in 
BT474 PTEN- LTT xenografts reduces MEOX1 expression at the protein level in vivo 
(Fig 4.4C, left), whereas parental BT474 tumors express no MEOX1 protein (Fig 4.4C, 
right).  Taken together, these results suggest that SF reduces MEOX1 expression at the 
mRNA and protein level both in vitro and in vivo.   
MEOX1 functionally regulates bulk cell line proliferation and BCSCs in vitro. 
To elucidate the function of MEOX1 in the trastuzumab resistant BT474 PTEN- LTT cell 
line its expression was reduced by siRNA knockdown, which reduced mRNA expression 
by more than 90% (Fig 4.5A).  The number of BT474 PTEN- LTT cells incubated with 
lipofectamine (vehicle), or lipofectamine and a non-targeted siRNA control (NT-control) 
increased 4-fold over the course of 72 hours (Fig 4.5B).  However, MEOX1 siRNA 
(siMEOX1) completely inhibited proliferation over the same time period as evident by 
the MTS assay.  To further evaluate the efficacy of MEOX1 knockdown on in vitro 
tumorigenicity the colony formation assay in soft agar was performed. Over 14 days the 
number of colonies from siMEOX treatment was reduced 86.7% relative to control 
treated BT474 PTEN- LTT cells (Fig 4.5C).  The role of MEOX1 in BCSC self-renewal 
was also determined using the mammospheres formation assay. Over the course of 7 days 
siMEOX treatment led to a 60.5% reduction in the number of mammospheres formed and 
the size of the average sphere was reduced by 90% (Fig 4.5D).  Taken together, these 
results suggest that MEOX1 is capable of regulating both CSCs and bulk cell line 
proliferation in trastuzumab resistant, PTEN deficient, breast cancers. 
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While the role of MEOX1 in regulating both cell line proliferation and CSCs was 
identified in trastuzumab resistant BT474 PTEN- LTT cells it is possible that, like SF, it 
may demonstrate utility in other cell lines.  The MDA-MB-453 cell line expresses HER2 
protein and contains mutations in PI3K and PTEN.  In this context it represents a cell line 
which may be predisposed to resistance against trastuzumab.  Further, previous work by 
Charafe-Jauffret et. al. have demonstrated that Aldefluor positive cells within this cell 
line accurately reflect CSCs (26).  Therefore we thought to determine if MEOX1 protein 
expression in this cell line correlates with ALDH1A1 expression.  Confocal microscopy 
of immunofluorescently labeled MDA-MB-453 cells reveals co-expression of MEOX1 
and ALDH1A1, albeit at different intracellular locations (Fig 4.5C, left). Quantification 
of fluorescent intensity for each individual channel identifies a linear correlation between 
protein expression (Spearman rho=0.797, p<0.01) (Fig 4.5C, right).  This suggests that 
MEOX1 may also play a role within CSCs in additional breast cancers. 
MEOX1 is significantly associated with TNBC and PTEN inactivation.   
MEOX1 demonstrated a critical functional role with respect to regulation of CSCs and 
proliferation of bulk cells in the BT474 PTEN- LTT cell line.  In addition, its presence in 
ALDH1A1 high cells in MDA-MB-453 suggested that MEOX1 expression may also be 
present in additional subtypes of breast cancer.  To expand the scope of our investigation 
MEOX1 staining was performed in a small TMA which contained paired normal cancer 
adjacent tissues and breast cancers from 75 different patients encompassing all major 
breast cancer subtypes.  Interestingly, no normal adjacent tissues or benign 
fibroadenomas exhibited MEOX1 expression (Fig 4.6A).  IHC staining revealed that 
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MEOX1+ cells can be found in 9.5% of tumor tissue from patients (Fig 4.6B, 7 out of 
75).  Of these seven patients five tumor samples were from TNBCs and grading ranged 
from ductal carcinoma in situ to node positive invasive carcinomas.  
In vitro MEOX1 expression can be identified in BT474 PTEN- LTT and MDA-MB-453 
cells, both of which contain reduced function of the PTEN tumor suppressor.  With this 
in mind we sought to determine if MEOX1 protein expression was inversely correlated 
with PTEN expression in patients.  TMA IHC staining (Fig 4.6C) demonstrated an 
inverse correlation between MEOX1 and PTEN (Spearman rho=-0.186, p<0.05).  Taken 
together with in vitro data, these results suggest that development of novel therapeutics 
which target MEOX1 may demonstrate clinical utility in patients predisposed to 
trastuzumab resistance via PTEN inactivation, those already resistant, and potentially a 
subset of TNBC patients. 
Discussion 
Cancer is currently estimated to be the leading cause of death worldwide and breast 
cancer is the 2
nd
 leading cause of cancer related deaths among women in the United 
States (27).  Identification of different breast cancer subtypes has led to significant 
advances in targeted therapy (28).  For HER2+ breast cancers several targeted therapies 
are currently in use with the front line therapy being trastuzumab.  While this antibody 
has proven extremely useful for early stage HER2+ breast cancer patients the majority of 
late stage (metastatic) patients demonstrate de novo resistance or will develop acquired 
resistance within 1 to 2 years (3-5).  Several mechanisms have been associated with the 
generation of trastuzumab resistance including antigen masking, activation of non-
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canonical HER2 binding partners, or activation of downstream signaling nodes which 
bypass the requirement for HER2.   
Accumulating evidence suggests that the induction of EMT and expansion of CSCs may 
be critical to the generation of trastuzumab resistance. For instance, JIMT-1 cells that 
exhibit de novo trastuzumab resistance express relatively high levels of EMT markers 
SLUG and SNAIL and are primarily CD44+/CD24-, whereas trastuzumab sensitive 
SKBR3 cells are primarily CD24+ and lack expression of EMT markers (29).  In another 
report associated with acquired resistance, 3 month culture of SKBR3 cells with 
trastuzumab generated drug resistance and resulted in expression of EMT inducer TGF-β 
and downstream target ZEB1 (30).  Further, Lesniak et al. demonstrated rare colonies 
within the SKBR3 cell line had spontaneously undergone EMT to generated drug 
resistance and the cells derived from these colonies were primarily CD44+/CD24- with 
lower HER2 expression (31). Numerous studies also have indicated that inactivation of 
PTEN genes may contribute to trastuzumab resistance.  In line with these studies our 
work, and that by Korkaya et. al., have established that induction of trastuzumab 
resistance by longer term trastuzumab culture in PTEN deficient cells rapidly induces 
EMT and expands CSCs (9).  While initially attributed to the activation of the IL-
6/STAT3/NF-kB positive feedback loop it is possible that additional signaling pathways 
may be critical to maintaining the observed phenotype.   
To further characterize pathways which may play a critical role in the trastuzumab 
resistance observed we surveyed the transcriptional landscape in parental BT474 and 
BT474 PTEN- LTT cell lines using RNA-Seq.  These experiments identified 3901 
differentially-expressed genes between the trastuzumab sensitive and resistant cell lines. 
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Utilizing bioinformatics analysis differentially expressed genes were categorized into 36 
canonical pathways.  From them, most up-regulated genes were significantly enriched for 
3 pathways including focal adhesion, ECM-receptor interaction and pathway in cancer 
progression.  These pathways in cancer progression included cytokine/NF-kB, HIF-1α, 
and WNT signaling, all of which are known to play a role in regulating breast CSCs(32-
35).  Conversely, following the generation of trastuzumab resistance expression of most 
ERBB receptors, their ligands, and genes classically associated with trastuzumab 
resistance either decreased or didn’t exhibit major changes in expression.  These results 
also confirm our previous observations that BT474 PTEN- LTT cells have adopted a 
TNBC subtype by undergoing the EMT.  Interestingly, we observed that expression of 
mRNA for breast cancer stem cell markers CD44+/CD24- was increased whereas 
ALDH1A1 and ALDH1A3 were dramatically decreased.  
Recently, Liu et. al. have identified that BCSCs exist in two distinct states: the MET state 
marked by the Aldefluor assay (proliferative with hypoxic niche) and the EMT state 
marked by CD44+/CD24- cell surface markers (quiescent with invasive characteristics) 
(36). However, the relative percentage of CSCs in the MET and EMT states may vary 
among cell lines (26, 36, 37).  We hypothesize that HER2+ breast cancers have shifted 
the equilibrium of CSCs primarily toward the MET like state, as evident by high 
percentages of ALDH+ cells (26) which giving rise to epithelial or luminal like cell 
markers and little to no CD44+/CD24- cells. This is supported by the observation that 
ALDH+ BCSCs rely on HER2 signaling for self-renewal (38). Conversely, in claudin-
low (triple negative) breast cancers the equilibrium is shifted primarily toward the EMT 
state giving rise to mesenchymal differentiated TNBCs in which greater than 90% of 
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cells with the cell line are CD44+/CD24- (37). Based on our previously mentioned data, 
and literature, we postulate that PTEN inactivation in HER2+ breast cancers expands the 
EMT-like CSC state. With both EMT and MET CSCs present the addition of trastuzumab 
shifts the equilibrium toward EMT state, by eliminating HER2 expressing cells, which 
upon differentiation create a mesenchymal triple negative cell line (Fig 4.7). 
Due to the dramatic alterations in gene expression between trastuzumab sensitive and 
resistant cell lines, and the numerous reported mechanisms of SF action, a knowledge 
based approach to determining critical pathways affected is difficult.  In order to take an 
unbiased approach toward identifying what genes are specifically inhibited to the largest 
extent by SF in the trastuzumab resistant cells we developed a treatment based filtering 
scheme to narrow our search.  Noting the relative sensitivity of both BT474 and BT474 
PTEN- LTT cell lines to SF we chose to focus on genes which were decreased in both a 
dose and time dependent manner by SF and were upregulated following trastuzumab 
resistance.  This filtering scheme allowed us to narrow our search to only 44 genes, 
which upon functional classification identified 4 homeobox transcription factors as 
potential targets.  Among them MEOX1 displaying the highest expression and fold-
change difference between parental and trastuzumab resistant cell lines and was therefore 
selected as the top candidate gene for further study. 
The MEOX1 (previously MOX1) homeobox transcriptional factor represents a critical 
mediator of normal somite formation in a developing embryo, a process which requires 
both the EMT and MET process (39-42). In patients, homozygous truncation mutations in 
the MEOX1 gene cause an autosomal-recessive form of Klippel-Feil Syndrome, a disease 
characterized by fusion of cervical vertebrae (43, 44).  Recent evidence in zebra fish 
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demonstrates MEOX1+ cells regulate normal hematopoietic stem cell formation in a 
cytokine dependent manner (45). Further, MEOX1 has been shown to mediate Hedgehog 
signaling by regulating Gli1/2 expression in cardiomyogenesis(46). While the role of 
MEOX-1 in cancer has largely been unexplored, one study by Thiaville et. al. suggests 
that this transcription factor partially mediates PBX1 signaling in ovarian cancers (21). 
PBX1 has been shown to be a downstream target of NOTCH signaling in breast cancer, 
and NOTCH itself is a known regulator of ALDH+ CSCs (47, 48). 
Validation of SF mediated MEOX1 suppression identified by RNA-seq was confirmed at 
the protein level in vitro via immunofluorescence and in an orthotopic mouse xenograft 
model in vivo.  To elucidate the functional of MEOX1, with respect to trastuzumab 
resistance, expression was reduced by siRNA knockdown in the BT474 PTEN- LTT cell 
line. Knockdown of MEOX1 significantly reduced bulk cell line proliferation, 
mammosphere formation, and colony formation in soft agar. These results indicate that 
MEOX1 plays a critical role both in regulating bulk cell line and the CSC within them. 
To further identify if MEOX1 may regulate CSCs in other HER2 expressing cell lines 
with PTEN inactivation its expression was associated with that of ALDH1A1 in MDA-
MB-453 cells.  Indeed, MEOX1 and ALDH1A1 exhibited a positive correlation in this 
cell line, suggesting that it may be capable of regulating CSCs in patients predisposed to 
trastuzumab resistance because of PTEN inactivation.  However, further studies are likely 
need to address this question.    
In order to survey the expression of MEOX1 in a broader patient population TMA 
staining of paired normal adjacent tissue and tumor samples was carried out.  Expression 
of MEOX1 was not identified in normal adult tissues or benign fibroadenomas.  
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However, MEOX1 expression was enriched in TNBC tissues at various stages of 
progression.  Using gene expression analysis of TNBC patient tissues Lehmann et. al. 
have demonstrated that TNBCs can be classified into six major subtypes (49).  
Interestingly, the mesenchymal stem-like subtype of TNBC they identified was 
characterized by the expression of HOX genes such as MEOX1.  This may suggest that 
the TNBCs identified to express MEOX1 in our TMA were of that TNBC subtype.  
Further, MEOX1 was inversely correlated with PTEN expression in patients.  These 
results are not surprising because in this context the discovery of MEOX1 took place in 
the BT474 PTEN- LTT cell line, which following generation of trastuzumab resistance 
via PTEN reduction ultimately became a TNBC.  In summary, we have identified 
MEOX1 as a novel drug target capable of regulating both bulk cell line proliferation and 
CSCs in trastuzumab resistant, PTEN deficient, breast cancers.  Taken together with our 
preliminary TMA data these results suggest MEOX1 may represent a novel drug target 
for the treatment of late stage HER2+ and a subset of TNBC patients.   
Methods 
Cell Lines and Reagents. BT474 was cultured in DMEM supplemented with 10% fetal 
bovine serum and 1% antibiotic-antimycotic under a 5% CO2 environment. BT474- 
PTEN- LTT cells, which were induced by shRNA knockdown of PTEN and long term 
treatment of trastuzumab, were maintained in the same media as the parental cell line. 
Sulforaphane was obtained from LKT Laboratories. Polyclonal antibodies against 
MEOX1 were purchased from Abcam (ab75895) and mouse anti-ALDH1A1 antibody 
was obtained from BD biosciences (611194). 
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RNA-seq data analysis. Total RNA was extracted using RNeasy Mini kit (Qiagen) and 
mRNA library was prepare for RNA-seq (poly A selection based) using Illumina TruSeq 
technology (Illumina). The generated libraries were sequenced on Illumina Hi-Seq 2000 
with 50 cycle single ended reads. RNA-Seq reads were aligned to annotated RefSeq(50) 
transcripts using Bowtie(51). Overall >80% of reads mapped to RefSeq transcripts and 
>95% were uniquely mapped. Only uniquely mapped reads were used for further 
analysis. Gene expression was expressed as reads/kilobase/million mapped reads 
(RPKM) (52) and differences in gene expression were estimated using rSeq(53). Gene set 
enrichment analysis was performed using the GSEA Java desktop software application 
(Broad Institute) (54, 55).  Finally, gene functional classification was performed using the 
DAVID Bioinformatics Resources v6.7 (56, 57). 
Knockdown by siRNA. Small interfering RNAs for gene MEOX1 was purchased from 
Qiagen (validated FlexiTube si RNA, SI00630266). siRNA amount varied by assay and 
was optimized relative to volume of total amount of media and transfection reagent used. 
Transfection of BT474 PTEN- LTT cells was carried out using Lipofectamine® 
RNAiMAX vehicle according to the manufacturer's instruction following optimization.  
As a negative control, a non-targeting sequence siRNA was utilized (Qiagen, catalog 
number 1027281).  Knockdown at mRNA level was confirmed by isolating total RNA 
(RNeasy Mini kit, Quigen), converting to cDNA (QuantiTect Rev. Transcription Kit, 
Qiagen), and performing real-time quantitative RT-PCR in triplicate.  Real-time PCR was 
carried out on an ABI PRISM 7900HT sequence detection system with 96-well block 
module and automation accessory (Applied Biosystems). 
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MTS Cell Proliferation Assay. Cell lines were seeded at a density of 3,000 cells per 
well in 96-well plates and allowed to adhere overnight. Cells were then incubated with 
SF in increasing concentrations for a period of 48 hours. Proliferation was determined by 
MTS assay according to manufacturer’s instruction by measuring the absorbance at 490 
nm on a Synergy 2 plate reader (Biotek). 
Advanced Tumor Model. All the mice in this study were conducted in accordance with 
a standard animal protocol approved by the University Committee on the Use and Care of 
Animals at the University of Michigan. 5 week old female non-obese diabetic/severe 
combined immunodeficient (NOD/SCID) mice were obtained from Jackson Laboratory. 
BT474 or BT474 PTEN- LTT cells (500,000) mixed with Matrigel (BD Biosciences) 
were injected to the mammary fat pads of NOD/SCID mice. Tumors were measured by 
caliper and the volume was calculated using V = 1/2 (width2 × length). When tumor 
volume reached approximately 40 mm3, the mice were randomly separated into two 
groups, once receiving daily i.p. injected with 0.9% saline solution and the other 
receiving 50 mg/kg sulforaphane daily.  Final tumor mass was measured on an analytical 
balance. 
Secondary Reimplantation. Isolated primary tumors were mechanically dissociated by 
mincing with scalpels and suspended in Media 199 (invitrogen). Single cell suspensions 
were generated by incubation with collagenase and hyaluronidase (Stem Cell 
Technologies) at 37oC for 45 min and passage through a 40 μm nylon mesh filter. 
Human tumor cells with DsRed label were then isolated using fluorescent activated cell 
sorting on a SY3200 (Sony Biotechnology) flow cytometer. Secondary female, 5 week 
old, NOD/SCID mice were inoculated with 5,000, 1,000, or 200 cells for BT474 PTEN- 
 123 
 
LTT xenografts as described above. Tumor formation rate in secondary mice was 
assessed 8 weeks following implanting cells by direct palpitation and used to assess 
cancer stem cell frequency by extreme limiting dilution analysis (58).  
Colony Formation Assay. Colony formation was carried out in six-well plates layered 
with 1.5 mL of 0.5% agar (Difco Agar Noble) in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. 
Subsequently, 1000 cells mixed with 0.35% agar and allowed to set in each well of the 
six-well plates in order to form the upper gel. After 2 weeks, pictures of colonies were 
taken using a digital camera after staining with 0.005% blue violet. Each treatment was 
performed in triplicate. 
Immunofluorescence. Cells were seated in glass chambers slides and allowed to adhere 
overnight. After rinsing with PBS, cells were fixed in PBS containing 4% 
paraformaldehyde for 30 minutes and permeabilized with 0.1% Triton X-100 (Roche 
Diagnostics) for 10 minutes at 4°C. Cells were then incubated with MEOX1 (1:200) 
primary antibodies, followed by FITC-conjugated anti-rabbit IgG (1:300) secondary 
antibodies. Samples were then mounted onto slides and visualized using confocal 
microscopy (Leica Microsystems).  Data shown represents the max intensity image.   
Mammosphere formation assay. Mammosphere culture was done as previously 
described in a serum-free mammary epithelium basal medium (Lonza, Inc.) 
supplemented with B27 (Invitrogen), 1% antibiotic-antimycotic, 5 μg/mL insulin, 1 
μg/mL hydrocortisone, 4 μg/mL gentamicin, 20 ng/mL EGF (Sigma-Aldrich), 20 ng/mL 
basic fibroblast growth factor (Sigma-Aldrich), and 1:25,000,000 β-mercaptoethanol 
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(Sigma-Aldrich)(59). Single cells prepared from mechanical and enzymatic dissociation 
were plated in six-well ultralow attachment plates (Corning) at a density of 500 cells/ml. 
After 7 days of culture, the number of mammospheres was counted on a Nikon Eclipse 
TE2000-S microscope and the photos were acquired with MetaMorph 7.6.0.0. 
Immunohistochemistry and Tissue Microarray Assay. Immunohistochemical analysis 
was performed on isolated tumors from mouse xenografts and patients tissues on a tissue 
micro array (TMA) obtained from US Biomax (BR1503b). Standard avidin-biotin 
complex peroxidase immunohistochemical staining (Histostain-Plus, Invitrogen) was 
performed according to manufacturer’s instruction. Briefly, after removal of paraffin in 
xylene and rehydration in graded alcohols, heated antigen retrieval was performed in 
citrate buffer (10 mmol/L pH 6.0) by waterbath heating for 30 min. Endogenous 
peroxidase activity was prevent by incubation in 0.3% hydrogen peroxide for 10 min. 
Nonspecific binding was blocked by incubation in 10% normal animal serum for 10 min. 
Sections were incubated at 4 °C for 24 h with each antibody. Correlation of MEOX1 and 
PTEN protein expression levels were initially scored by intensity and the percentage of 
immunoreactive cells. Tissues with no staining were rated as 0, with faint staining or 
moderate to strong staining in <25% of cells as 1, with moderate staining or strong 
staining in 25% to 50% of cells as 2, and with strong staining in >50% of cells as 3. 
Breast cancer tissues that registered levels 0 and 1 were defined as negative for 
expression, whereas samples at levels 2 or 3 were defined as positive. 
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Figure 4.1 Trastuzumab resistance activates diverse signaling pathways and alters 
BCSC marker expression.  A) Left, heat map representation of the differentially 
expressed genes between BT474 and BT474 PTEN- LTT cell lines, gene expression is 
shown with pseudocolor scale (−3 to 3) with red denoting high gene expression levels.  
Right, the top ranking gene ontology attributes enriched in upregulated and down 
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regulated genes with associated p values. B) Gene set enrichment analysis identifying 
enrichment of upregulated genes in BT474 PTEN- LTT cells (Top) and those 
downregulated (Bottom) pertaining to EMT and molecular subtype. C) Mammosphere 
formation rates of parental BT474 and BT474 PTEN- LTT cell lines. D)  Representative 
image of macrometastasis that forms in 1 in 5 mice BT474 PTEN- LTT xenograft bearing 
mice before primary tumors reach 500 mm
3
.  E) RNA expression of common BCSC 
markers determined by RNA-seq expressed as reads/kilobase/million mapped reads 
(RPKM).  N=4. Data shown as average ± SD. # p ≤ 0.01. 
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Figure 4.2 Generation of trastuzumab resistance from BT474 with PTEN deletion 
reduces ERBB family receptors and ligands with modest change in classical 
mechanisms associated with resistance. Normalized mRNA expression 
(reads/kilobase/million reads) of (A) ERBB family members HER3, HER4, and EGFR 
with corresponding major ligands and (B) genes previously associated with antigen 
masking on HER2 and resistance induced signaling crosstalk, MUC4 and IGF1R 
respectively.  N=4. Data shown as average ± SD. * p ≤ 0.05, # p ≤ 0.01 
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Figure 4.3 Sulforaphane preferentially inhibits Homeobox transcription factors in 
trastuzumab resistant cells.  A) Cell viability of BT474 and BT474 PTEN- LTT cell 
lines following 72 hour treatment with SF as determined by the MTS assay. N=6.  B) 
Schematic of treatment groups for RNA-sequencing to identify both time (10 μM SF 8 
hours v.s. 10 μM SF 24 hours) and dose (2 μM SF 24 hours v.s. 10 μM SF for 24 hours).  
N=4.  C) Venn diagram illustrating number of genes reduced 2-fold in BT474 PTEN- 
LTT cells following each treatment.  D) Heat map illustrating expression changes in 
BT474 and BT474 PTEN- LTT cells of the 110 genes which are inhibited in a dose and 
time dependent manner by 2-fold after SF treatment.  Red box highlights the 44 genes 
which were also upregulated in the BT474 PTEN- LTT cell line.  E) mRNA expression 
level of the 4 homeobox transcription factors which were functionally enriched from the 
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44 gene set.  N=4. Data shown as average ± SD. # p ≤ 0.01 from t test between BT474 
and BT474 PTEN- LTT. 
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Figure 4.4 Sulforaphane inhibits MEOX1 protein expression in vitro and in vivo. A) 
Representative Immunofluorescent imaging of fixed BT474 PTEN- LTT cells following 
24 hours in the presence of absence of SF. MEOX1 (green) resides primarily within the 
nucleus as evident by overlap with DAPI (Blue) staining. Images obtained originally with 
40X objective.  B) Left, final tumor of orthotopic mouse xenografts treated with daily I.P. 
administration of 0.9% saline or 50 mg/kg SF.  N=5.  Data shown as average ± SD. * p ≤ 
0.05.  Right, tumor formation rates in secondary untreated mice 8 weeks following 
implantation of residual cells from primary tumors.  C) Representative IHC staining of 
MEOX1 from control or SF treated primary xenografts counter stained with hematoxylin 
and eosin. 
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Figure 4.5 MEOX1 regulates bulk cell line proliferation and BCSCs in cell lines with 
reduced PTEN activity in vitro.  A) Real time PCR analysis of MEOX1 mRNA 
expression relative to GAPDH in BT474 PTEN- LTT cells treated with transfection 
reagent (Vehicle), non-targeted siRNA control (NT-control), or siRNA for MEOX1 
(siMEOX1).  N=3.  B) Proliferation of BT474 PTEN- LTT cells in the presence of 
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vehicle, NT-control, or siMEOX1 over the course of 42 hours as determined by MTS 
proliferation assay.  N=3.  C) Top, representative images of colonies formed after 14 days 
from BT474 PTEN- LTT cells treated with vehicle, NT-control, or siMEOX1for 24 
hours.  Bottom, quantification of number of colonies formed after 14 days of culture in 
soft agar.  N=3. D) Top, representative images of mammospheres formed after 7 days 
from BT474 PTEN- LTT cells treated with vehicle, NT-control, or siMEOX1for 24 
hours.  Bottom, quantification of number of mammospheres formed after 7 days of 
culture in serum free non-adherent conditions.  N=3. Data shown as average ± SD. * p ≤ 
0.05, # p ≤ 0.01.  E) Left, representative maximum intensity confocal microscopy image 
of MDA-MB-453 cell line stained for MEOX1 (Green), ALDH1A1 (Red), and DAPI 
(Blue).  Right, corrected total cell fluorescence (CTCF) of MEOX1 and ALDH1A1 for 
each individual MDA-MB-453 shown. N=16. Spearman rho = 0.797, p<0.01. 
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Figure 4.6 MEOX1 is present in a subset of TNBCs and is inversely correlated with 
PTEN expression.  A) Representative immunohistochemical (IHC) staining of MEOX1 
in cancer adjacent normal tissue and benign fibro adenomas in a 75 patients tissue 
microarray. No obvious staining was observed in these types of tissue.  B) Representative 
image of 3/7 breast cancer tissues which stained positive for MEOX1, only TNBCs 
shown. T – size and invasive status of primary tumor, N – metastasis to regional lymph 
nodes, M – distant metastasis. C) Representative image of IHC staining in the same tissue 
for both MEOX1 and PTEN.    
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Figure 4.7 Proposed model of alterations in BT474 cells during generation of 
trastuzumab resistance. The parental trastuzumab sensitive BT474 (HER2+/PTEN+) 
cell line exhibits primarily epithelial morphology and are derived from an MET-like 
BCSC (ALDH+) (Blue).  PTEN inactivation results in both EMT-like (CD44+/CD24-) 
and MET-like BCSC (ALDH+) that give rise to heterogeneous cell populations with both 
epithelial and mesenchymal characteristics (Pink).  Trastuzumab treatment (to generate 
complete resistance) in the BT474 shPTEN cell line drives BCSCs to the EMT-like state 
that differentiate giving rise to a mesenchymal TNBC cell line (Red). These trastuzumab-
resistant PTEN- breast cancers are sensitive to sulforaphane and upregulate MEOX1 to 
regulate bulk cell line proliferation and BCSCs.    
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Chapter 5 
Conclusions  
Summary of Findings and Clinical Implications 
Due to advances in early diagnosis, surgical techniques, and the development of novel 
targeted therapeutic agents, overall survival of breast cancer patients has been steadily 
improving since the late 1980s (1).   Advances in targeted therapies have also improved 
the quality of life for patients by reducing symptoms associated with conventional 
cytotoxic chemotherapies (2).  However, in spite of all these improvements metastatic 
breast cancer is still largely an incurable disease.  While targeted therapies have greatly 
benefited patients with Luminal A, Luminal B, and HER2+ breast cancers, no such 
therapies exist for the treatment of triple negative breast cancers (TNBCs) (3).  
Unfortunately for patients with advanced stage disease, once a malignancy becomes 
resistant to primary treatment relapse in additional lines of therapy often occur more 
rapidly (4).  Throughout this dissertation it has been proposed that resistance after 
primary therapy can be predominantly explained by the expansion of breast cancer stem 
cells (BCSCs); in the case of trastuzumab resistance, this may actually alter the molecular 
subtype of the cancer.   
In Chapter 2 of this dissertation we identify that cytotoxic chemotherapy with docetaxel 
increases CD44+/CD24-/EpCAM+ and ALDH+ BCSCs in TNBCs.  This observation is 
proposed to occur through induced expression of IL-6 following therapy, which is known 
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to expand BCSCs (5, 6).  Following a comprehensive evaluation of the efficacy of the 
natural product sulforaphane (SF) in the four major subtypes of breast cancer, we identify 
that SF preferentially inhibits TNBCs and HER2+ breast cancers with a concomitant 
activation of AKT (PI3K activating mutation of PTEN inactivation).  Further, SF is 
capable of inhibiting ALDH+ BCSCs across breast cancer subtypes at concentrations >5-
fold lower than the respective bulk cell line IC50.  Inhibition of NF-kB by SF is evident 
by blockade of intracellular translocation following TNF-α stimulation and, at the 
transcriptional level, by reduction in an NF-kB reporter system and endogenous target IL-
6.  In combination SF potentiates docetaxel’s efficacy in bulk cell lines, prevents 
docetaxel-induced IL-6 expression, and reduces the ALDH+ BCSC population in vitro.  
In an advanced treatment orthotopic mouse xenograft model, docetaxel reduces bulk 
tumor volume, but expands BCSCs as evident by extreme limiting dilution (ELDA) 
analysis in secondary mice.  Treatment with combination therapy is more effective at 
reducing bulk tumor volume and BCSCs than any single agent. 
These findings raise concern for continued use of docetaxel in the neo-adjuvant setting 
for TNBC patients.  We propose a potential explanation to, and possible solution for, the 
so called “triple negative breast cancer paradox.” This phenomenon is named for the 
observation that TNBCs tend to achieve higher rates of pathologic complete response 
(pCR) than other breast cancer subtypes, but those who do not exhibit pCR have worse 
overall survival following primary chemotherapy (7-9). In these patients docetaxel may 
increase BCSCs, leading to rapid recurrence at local and metastatic sites and ultimately 
reducing overall patient survival.  By demonstrating that SF is capable of preventing this 
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phenomenon, we provide a convenient pharmacologic intervention which can supplement 
current clinical practice for more effective treatment of TNBCs.    
In Chapter 3 of this dissertation we confirm previous studies demonstrating that 
generation of trastuzumab resistance in HER2+/PTEN- breast cancers induces the 
epithelial to mesenchymal transition (EMT) and expands CD44+/CD24- BCSCs (6, 10-
12).  Following induction of EMT trastuzumab-resistant, PTEN-deficient, cells adopt a 
triple negative phenotype in vitro and in vivo.  This subtype switching from HER2+ to 
TNBC is associated with reduced expression of major ERBB family receptors and 
ligands, and activation of the IL-6/STAT3/NF-kB positive feedback loop.  As in the case 
of TNBC from Chapter 2, we further demonstrate the ability of SF to inhibit NF-kB 
activity across breast cancer subtypes.  We hypothesized that the efficacy of SF is 
determined by the relative dependence of a given cell line on NF-kB signaling for 
survival.  While SF fails to eliminate HER2+/PTEN+ breast cancers in vitro it becomes 
increasingly effective as trastuzumab resistance develops, to the same extent as observed 
in the most sensitive cell lines from Chapter 2.  Much like the efficacy in TNBCs 
docetaxel significantly reduces bulk tumor volume of trastuzumab-resistant breast cancer 
cell lines grown as xenografts, whereas for negative control xenografts trastuzumab has 
no effect on tumor volume.  Interestingly, in this setting SF reduces bulk tumor volume to 
the same extent as docetaxel.  Utilizing ELDA in secondary mice, we show that 
trastuzumab significantly increases the frequency of BCSCs whereas SF significantly 
reduces them.  In trastuzumab-sensitive BT474 xenografts, SF only modestly reduces 
bulk tumor volume; this result is comparable to our observations of SF efficacy in the in 
vitro MTS assay.  In an early treatment xenograft model, SF prevents the engraftment of 
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tumors in a dose-dependent manner for trastuzumab-resistant breast cancer; those tumors 
which do form progress at a dramatically slower rate.  This phenomenon is persistent 
even after SF treatment is discontinued, confirming SF effectively reduces BCSCs in 
vivo. 
These results have critical implications for the treatment of HER2+ breast cancers in late 
stage patients who exhibit PTEN inactivation.  While in current practice the functional 
activity of PTEN is not considered when prescribing trastuzumab, our results suggest that 
in these patients trastuzumab treatment will ultimately lead to worse patient prognoses. 
We propose that this would be a result of EMT induction, expansion of BCSCs, and 
conversion of the disease to a triple negative phenotype.  If this is ultimately true in 
trastuzumab-resistant PTEN- patients, it would imply that traditional second-line targeted 
therapies such as pertuzumab, TDM-1, and lapatinib would provide little benefit in the 
long run because they all rely on binding to HER2 (and EGFR in the case of lapatinib) 
and its expression would no longer be present.  Due to the reliance of the transformed 
cells on the IL-6/NF-kB positive feedback loop we demonstrate that SF has a marked 
increase in efficacy after drug resistance has developed. Therefore, in the event that 
trastuzumab resistance develops in PTEN deficient patients, we have provided a rational 
therapy which can be exploited for further treatment.   
In Chapter 4 of this dissertation we explore the possibility that trastuzumab-resistant 
breast cancers with PTEN inactivation may be dependent on more than just the IL-
6/STAT3/NF-kB positive feedback loop. Strikingly, nearly 4,000 genes are differentially 
expressed between parental HER2+ BT474 and the trastuzumab-resistant BT474 
generated by stable PTEN knockdown and long term culture with trastuzumab.  We show 
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that the drug-resistant cell line has dramatically reduced expression of the ALDH 
enzymes which serve as markers for MET-like BCSCs, and higher expression of CD44 
(with a concomitant reduction in CD24) which serves as a marker for EMT-like BCSCs.  
This suggests that the dynamics of BCSCs (13) may play a role in the generation of a 
TNBC phenotype, observed in Chapter 3, following trastuzumab resistance.  In order to 
evaluate which genes are critical to proliferation and regulation of BCSCs in this model 
we exploit the fact that the trastuzumab-resistant cell line is remarkably more sensitive to 
SF.  By RNA-sequencing analysis we identify that SF preferentially inhibits homeobox 
transcription factors in the drug-resistant cell line in both a time- and dose-dependent 
manner.   Of these genes, MEOX1 was selected as the top candidate for further study.  In 
order to demonstrate the SF-mediated suppression of MEOX1 at the protein level, we 
perform immunofluorescent staining in vitro and immunohistochemical staining of 
tumors from xenograft-bearing mice.  Further, with siRNA knockdown we demonstrate 
that MEOX1 is functionally capable of regulating bulk cell line proliferation as well as 
BCSCs in vitro.   Finally, knowing that SF is capable of inhibiting BCSCs across breast 
cancer subtypes and that MEOX1 was discovered in a TNBC cell line (generated by 
trastuzumab resistance), we expanded our search for potential applications of MEOX1-
based therapies.  Using confocal microscopy we demonstrate that MEOX1 is correlated 
with ALDH expression in an additional epithelial-like cell line harboring a PTEN 
inactivation mutation.  Further, using a tissue micro array of patient samples we identify 
that MEOX1 is expressed in a subset of TNBCs and is inversely correlated with PTEN 
expression.   
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Using this unbiased approach we confirm our previous results in Chapter 3, indicating 
that trastuzumab resistance indeed results in the EMT, expands BCSCs, and converts 
HER2+ breast cancer to a TNBC subtype. If true in patients the use of trastuzumab in late 
stage HER2+ breast cancer patients with PTEN inactivation would ultimately be 
counterproductive in terms of improving long term survival.  However, by coupling bulk 
cell line gene expression changes with those resulting from specific inhibition of the 
trastuzumab-resistant cell line we identify MEOX1 as a novel potential drug target for 
these patients.  With MEOX1 capable of regulating both bulk cell line proliferation and 
BCSCs it may be unnecessary to use combination treatment strategies, such as those in 
Chapter 1, in these patients.  Ultimately additional studies would be necessary to truly 
validate MEOX1 signaling as a bona fide drug target for the development of novel 
therapeutics.  However, these studies provide a framework for future drug discovery 
efforts aimed at the treatment of trastuzumab resistance and potentially a subset of 
TNBCs.    
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